



HU000029448T2



(19) **HU**

(11) Lajstromszám: **E 029 448**

(13) **T2**

**MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala

## **EURÓPAI SZABADALOM** **SZÖVEGÉNEK FORDÍTÁSA**

(21) Magyar ügyszám: **E 07 824232**

(22) A bejelentés napja: **2007. 10. 18.**

(96) Az európai bejelentés bejelentési száma:  
**EP 20070824232**

(97) Az európai bejelentés közzétételi adatai:  
**EP 2076539 A2** **2008. 04. 24.**

(97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2076539 B1** **2016. 06. 08.**

(51) Int. Cl.: **C07K 16/24**

(2006.01)  
**A61K 393/95** (2006.01)

**A61P 35/00** (2006.01)

**C12N 15/13** (2006.01)

**A61P 37/06** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/GB 07/003983**

(87) A nemzetközi közzétételi szám:

**WO 08047134**

(30) Elsőbbségi adatai:  
**0620729** **2006. 10. 18.** **GB**

(73) Jogosult(ak):  
**UCB Biopharma SPRL, 1070 Brussels (BE)**

(72) Feltaláló(k):

**ADAMS, Ralph, Slough Berkshire SL1 3WE (GB)**  
**POPPLEWELL, Andrew George, Slough Berkshire SL1 3WE (GB)**  
**RAPECKI, Stephen Edward, Slough Berkshire SL1 3WE (GB)**

(74) Képviselő:  
**Danubia Szabadalmi és Jogi Iroda Kft., Budapest**

(54)

**IL-17A-t és IL-17F-t kötő ellenanyag-molekulák**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(19)



(11)

EP 2 076 539 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:  
**08.06.2016 Bulletin 2016/23**

(21) Application number: **07824232.8**(22) Date of filing: **18.10.2007**

(51) Int Cl.:  
**C07K 16/24 (2006.01) A61K 39/395 (2006.01)**  
**C12N 15/13 (2006.01) A61P 37/06 (2006.01)**  
**A61P 35/00 (2006.01)**

(86) International application number:  
**PCT/GB2007/003983**

(87) International publication number:  
**WO 2008/047134 (24.04.2008 Gazette 2008/17)**

(54) **ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F**

ANTIKÖRPERMOLEKÜLE, DIE AN IL-17A UND IL-17F BINDEN

MOLÉCULES D'ANTICORPS QUI SE LIENT À IL-17A ET À IL-17F

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
 HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE  
 SI SK TR**  
 Designated Extension States:  
**AL BA HR MK RS**

(30) Priority: **18.10.2006 GB 0620729**(43) Date of publication of application:  
**08.07.2009 Bulletin 2009/28**(60) Divisional application:  
**12175103.6 / 2 514 764**(73) Proprietor: **UCB Biopharma SPRL  
 1070 Brussels (BE)**

(72) Inventors:

- **ADAMS, Ralph**  
**Slough Berkshire SL1 3WE (GB)**
- **POPPEWELL, Andrew George**  
**Slough Berkshire SL1 3WE (GB)**
- **RAPECKI, Stephen Edward**  
**Slough Berkshire SL1 3WE (GB)**

(74) Representative: **Thompson, John et al**  
**UCB Celltech,**  
**208 Bath Road**  
**Slough, Berkshire SL1 3WE (GB)**

(56) References cited:  
**WO-A-2005/010044 WO-A-2006/088833**  
**WO-A-2007/106769**

- **HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, November 2003 (2003-11), pages 484-490, XP004467495 ISSN: 0167-7799**
- **DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, September 1996 (1996-09), pages 169-179, XP004070292 ISSN: 1380-2933**
- **"Anti-human II-17 antibody" 28 August 2007 (2007-08-28), R&D SYSTEMS, INC , XP002474646 ISBN: 1-800-343-7475 Retrieved from the Internet: URL:<http://www.rndsystems.com/pdf/af317na.pdf> [retrieved on 2008-03-27] the whole document**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

**[0001]** The present invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.

**[0002]** Interleukin 17 (IL-17), also known as CTLA-8 or IL-17A, is a pro-inflammatory cytokine which stimulates the secretion of a wide range of other cytokines from various non-immune cells. IL-17A is capable of inducing the secretion of IL-6, IL-8, PGE2, MCP-1 and G-CSF by adherent cells like fibroblasts, keratinocytes, epithelial and endothelial cells and is also able to induce ICAM-1 surface expression, proliferation of T cells, and growth and differentiation of CD34+ human progenitors into neutrophils when cocultured in the presence of irradiated fibroblasts (Fossiez et al., 1998, Int.Rev.Immunol. 16, 541-551). IL-17A is predominantly produced by activated memory T cells and acts by binding to a ubiquitously distributed cell surface receptor (IL-17R) (Yao et al., 1997, Cytokine, 9, 794-800). It may also act through binding to a complex of IL-17RA and IL-17RC (Toy et al., 2006, J. Immunol. 177(11):36-39). IL-17 producing T cells called 'TH17 cells' have been implicated in the pathogenesis of certain cancers (Weaver et al., 2006, Immunity, 24, 677-688; Langowski et al., 2006, 442, 461-465; Iwakura and Ishigame, 2006, J.Clin.Invest. 116, 5, 1218-1222).

**[0003]** A number of homologues of IL-17 have been identified which have both similar and distinct roles in regulating inflammatory responses. For a review of IL-17 cytokine/receptor families see Dumont, 2003, Expert Opin. Ther. Patents, 13, 287-303. One such homologue is IL-17F, also known as IL-24 and ML-1, which is around 55% identical to IL-17A and is thought to share the same receptors as IL-17A (Kolls and Linden 2004, Immunity, 21, 467-476; Hymowitz, et al., 2001, EMBO J. 20(19), 5332-5341; Kuestner et al., 2007, Journal of Immunology, 179, 5462-5473).

**[0004]** Both IL-17A and IL-17F can form both homodimeric and heterodimeric proteins, all of which are produced by activated human CD4+ T cells (Wright et al., 2007, J Biol Chem. 282 (18), 13447-13455).

**[0005]** IL-17 may contribute to a number of diseases mediated by abnormal immune responses, such as rheumatoid arthritis and air-way inflammation, as well as organ transplant rejection and antitumour immunity. Inhibitors of IL-17 activity are well known in the art for example a murine IL-17R:human Fc fusion protein, a murine soluble IL-17R and an anti-IL-17 monoclonal antibody have been used to demonstrate the role of IL-17 in various models of rheumatoid arthritis (Lubberts et al., J.Immunol. 2001, 167, 1004-1013; Chabaud et al., Arthritis Res. 2001, 3, 168-177). In addition, neutralising polyclonal antibodies have been used to reduce peritoneal adhesion formation (Chung et al., 2002, J. Exp. Med., 195, 1471-1478). Rat derived anti-human IL-17 antibodies were described in WO04/106377. A humanised anti-IL-17 antibody with an affinity of around 220pM was described in WO2006/054059. A monoclonal anti-IL-17 fully human antibody with an affinity of around 188pM was described in WO2006/013107. Antibodies which bind IL-17F and IL-17A/IL-17F heterodimers were described in WO2006/088833. Antibodies which specifically bind the IL-17A/IL-17F heterodimer were described in WO2005/010044.

**[0006]** IL-17F antagonism has been associated with protection against asthma (Kawaguchi et al., 2006, J.Allergy Clin. Immunol. 117(4); 795-801) and IL-17F is also thought to play a role in arthritis pathology (Lubberts 2003, Current Opinion in Investigational Drugs, 4 (5), 572-577).

**[0007]** Accordingly dual antagonists of IL-17A and IL-17F may be more effective than a sole antagonist in treating IL-17 mediated diseases. Antibodies which bind IL-17A and IL-17F were described in WO2007/106769 published 20.9.07. Goat polyclonal IgG antibodies to human IL-17 are available from R&D Systems, Catalog Number: AF-317-NA.

**[0008]** We have been able to demonstrate that it is possible to isolate an antibody which is capable of binding to both IL-17A and IL-17F and is capable of neutralising the activity of both isoforms of IL-17. Hence the present disclosure provides an anti-IL-17 antibody which is capable of binding to both IL-17A and IL-17F. In particular there is provided a neutralising antibody which binds human IL-17A and human IL-17F, comprising a heavy chain and a light chain wherein the heavy chain variable domain comprises the sequence given in SEQ ID NO:9 and the light chain variable domain comprises the sequence given in SEQ ID NO:7 or a sequence at least 95% identical thereto and wherein the antibody has an affinity for IL-17A of better than 20pM and an affinity for IL-17F of better than 2nM.

**[0009]** In particular, the antibody of the present invention is capable of specifically binding to both IL-17A and IL-17F i.e. the antibody does not bind to other isoforms of IL-17. Preferably the antibody of the present invention also binds the IL-17A/IL-17F heterodimer. Preferably, the antibody of the present invention neutralises the activity of both IL-17A and IL-17F. In one embodiment the antibody of the present invention also neutralises the activity of the IL-17A/IL-17F heterodimer. The antibodies of the present invention therefore have the advantageous property that they can inhibit the biological activity of both IL-17A and IL-17F. Accordingly, the present invention also provides the use of such antibodies in the treatment of and/or prophylaxis of a disease mediated by either or both of IL-17A or IL-17F such as autoimmune or inflammatory disease or cancer.

**[0010]** As used herein, the term 'neutralising antibody' describes an antibody that is capable of neutralising the biological signalling activity of both IL-17A and IL-17F for example by blocking binding of IL-17A and IL-17F to one or more of their receptors and by blocking binding of the IL-17A/IL-17F heterodimer to one or more of its receptors. It will be appreciated that the term 'neutralising' as used herein refers to a reduction in biological signalling activity which may be partial or

complete. Further, it will be appreciated that the extent of neutralisation of IL-17A and IL-17F activity by the antibody may be the same or different. In one embodiment the extent of neutralisation of the activity of the IL-17A/IL-17F heterodimer may be the same or different as the extent of neutralisation of IL-17A or IL-17F activity.

**[0011]** In one embodiment the antibodies of the present invention specifically bind to IL-17A and IL-17F. Specifically binding means that the antibodies have a greater affinity for IL-17A and IL-17F polypeptides (including the IL-17A/IL-17F heterodimer) than for other polypeptides. Preferably the IL-17A and IL-17F polypeptides are human. In one embodiment the antibody also binds cynomolgus IL-17F.

**[0012]** IL-17A or IL-17F polypeptides or a mixture of the two or cells expressing one or both of said polypeptides can be used to produce antibodies which specifically recognise both polypeptides. The IL-17 polypeptides (IL-17A and IL-17F) may be 'mature' polypeptides or biologically active fragments or derivatives thereof which preferably include the receptor binding site. Preferably the IL-17 polypeptides are the mature polypeptides. IL-17 polypeptides may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems or they may be recovered from natural biological sources. In the present application, the term "polypeptides" includes peptides, polypeptides and proteins. These are used interchangeably unless otherwise specified. The IL-17 polypeptide may in some instances be part of a larger protein such as a fusion protein for example fused to an affinity tag. Antibodies generated against these polypeptides may be obtained, where immunisation of an animal is necessary, by administering the polypeptides to an animal, preferably a non-human animal, using well-known and routine protocols, see for example Handbook of Experimental Immunology, D. M. Weir (ed.), Vol 4, Blackwell Scientific Publishers, Oxford, England, 1986). Many warm-blooded animals, such as rabbits, mice, rats, sheep, cows or pigs may be immunized. However, mice, rabbits, pigs and rats are generally preferred.

**[0013]** Antibodies for use in the present invention include whole antibodies and functionally active fragments or derivatives thereof and may be, but are not limited to, monoclonal, multi-valent, multi-specific, humanized or chimeric antibodies, domain antibodies e.g. VH, VL, VHH, single chain antibodies, Fab fragments, Fab' and F(ab')<sub>2</sub> fragments and epitope-binding fragments of any of the above. Other antibody fragments include those described in International patent applications WO2005003169, WO2005003170 and WO2005003171. Antibody fragments and methods of producing them are well known in the art, see for example Verma et al., 1998, Journal of Immunological Methods, 216, 165-181; Adair and Lawson, 2005. Therapeutic antibodies. Drug Design Reviews - Online 2(3):209-217.

**[0014]** Antibodies for use in the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.* molecules that contain an antigen binding site that specifically binds an antigen. The immunoglobulin molecules of the invention can be of any class (e.g. IgG, IgE, IgM, IgD and IgA) or subclass of immunoglobulin molecule.

**[0015]** Monoclonal antibodies may be prepared by any method known in the art such as the hybridoma technique (Kohler & Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today, 4:72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, pp77-96, Alan R Liss, Inc., 1985).

**[0016]** Antibodies for use in the invention may also be generated using single lymphocyte antibody methods by cloning and expressing immunoglobulin variable region cDNAs generated from single lymphocytes selected for the production of specific antibodies by for example the methods described by Babcock, J. et al., 1996, Proc. Natl. Acad. Sci. USA 93(15):7843-7848; WO92/02551; WO2004/051268 and International Patent Application number WO2004/106377.

**[0017]** Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule (see, *e.g.* US 5,585,089; WO91/09967).

**[0018]** Chimeric antibodies are those antibodies encoded by immunoglobulin genes that have been genetically engineered so that the light and heavy chain genes are composed of immunoglobulin gene segments belonging to different species. These chimeric antibodies are likely to be less antigenic. Bivalent antibodies may be made by methods known in the art (Milstein et al., 1983, Nature 305:537-539; WO 93/08829, Traunecker et al., 1991, EMBO J. 10:3655-3659). Multi-valent antibodies may comprise multiple specificities or may be monospecific (see for example WO 92/22853 and WO05/113605).

**[0019]** The antibodies for use in the present invention can also be generated using various phage display methods known in the art and include those disclosed by Brinkman et al. (in J. Immunol. Methods, 1995, 182: 41-50), Ames et al. (J. Immunol. Methods, 1995, 184:177-186), Kettleborough et al. (Eur. J. Immunol. 1994, 24:952-958), Persic et al. (Gene, 1997 187 9-18), Burton et al. (Advances in Immunology, 1994, 57:191-280) and WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and US 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108. Techniques for the production of single chain antibodies, such as those described in US 4,946,778 can also be adapted to produce single chain antibodies which bind to IL-17A and IL-17F. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

**[0020]** The residues in antibody variable domains are conventionally numbered according to a system devised by

Kabat *et al.* This system is set forth in Kabat *et al.*, 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereafter "Kabat *et al. (supra)*"). This numbering system is used in the present specification except where otherwise indicated.

**[0021]** The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a "standard" Kabat numbered sequence.

**[0022]** The CDRs of the heavy chain variable domain are located at residues 31-35 (CDR-H1), residues 50-65 (CDR-H2) and residues 95-102 (CDR-H3) according to the Kabat numbering system. However, according to Chothia (Chothia, C. and Lesk, A.M. *J. Mol. Biol.*, 196, 901-917 (1987)), the loop equivalent to CDR-H1 extends from residue 26 to residue 32. Thus 'CDR-H1', as used herein, comprises residues 26 to 35, as described by a combination of the Kabat numbering system and Chothia's topological loop definition.

**[0023]** The CDRs of the light chain variable domain are located at residues 24-34 (CDR-L1), residues 50-56 (CDR-L2) and residues 89-97 (CDR-L3) according to the Kabat numbering system.

**[0024]** In one embodiment the disclosure provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO: 1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.

**[0025]** In another embodiment the present disclosure provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a light chain, wherein the variable domain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.

**[0026]** The antibody molecules of the present disclosure preferably comprise a complementary light chain or a complementary heavy chain, respectively.

**[0027]** Hence in one embodiment, an antibody comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.

**[0028]** It will be appreciated that one or more amino acid substitutions may be made to the CDRs provided by the present disclosure without significantly altering the ability of the antibody to bind to IL-17A and IL-17F and to neutralise IL-17A and IL-17F activity. The effect of any amino acid substitutions on binding and neutralisation can be readily tested by one skilled in the art, for example by using the methods described herein. Accordingly, the present disclosure provides an antibody comprising CDRs selected from CDRH-1 (SEQ ID NO:1), CDRH-2 (SEQ ID NO:2), CDRH-3 (SEQ ID NO:3), CDRL-1 (SEQ ID NO:4), CDRL-2 (SEQ ID NO:5) and CDRL-3 (SEQ ID NO:6) in which one or more amino acids in one or more of the CDRs has been substituted with another amino acid. It will also be appreciated that the length of one or more of the CDRs may be altered without significantly altering the ability of the antibody to bind to IL-17A and IL-17F and to neutralise IL-17A and IL-17F activity.

**[0029]** In one embodiment, an antibody of the present disclosure comprises a heavy chain, wherein the variable domain of the heavy chain comprises three CDRs wherein the sequence of CDRH-1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:1, CDRH-2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:2 and/or CDRH-3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:3. In another embodiment, an antibody of the present disclosure comprises a heavy chain, wherein the variable domain of the heavy chain comprises three CDRs wherein the sequence of CDRH-1 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:1, CDRH-2 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:2 and/or CDRH-3 has at least 70%, 80%, 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:3.

**[0030]** "Identity", as used herein, indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity", as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for isoleucine or valine. Other amino acids which can often be substituted for one another include but are not limited to:

- phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains);
- lysine, arginine and histidine (amino acids having basic side chains);
- aspartate and glutamate (amino acids having acidic side chains);
- asparagine and glutamine (amino acids having amide side chains); and

- cysteine and methionine (amino acids having sulphur-containing side chains). Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heijne, G., Academic Press, 1987; and Sequence Analysis Primer, Gribkoff, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

5 [0031] In one embodiment the antibody provided by the present disclosure is a monoclonal antibody.

[0032] In one embodiment the antibody provided by the present disclosure is a chimeric antibody.

10 [0033] In one embodiment the antibody provided by the present disclosure is a CDR-grafted antibody molecule comprising one or more of the CDRs provided in SEQ ID NOS:1 to 6. As used herein, the term 'CDR-grafted antibody molecule' refers to an antibody molecule wherein the heavy and/or light chain contains one or more CDRs (including, if desired, one or more modified CDRs) from a donor antibody (e.g. a murine monoclonal antibody) grafted into a heavy and/or light chain variable region framework of an acceptor antibody (e.g. a human antibody). For a review, see Vaughan et al, *Nature Biotechnology*, 16, 535-539, 1998. In one embodiment rather than the entire CDR being transferred, only one or more of the specificity determining residues from any one of the CDRs described herein above are transferred to the human antibody framework (see for example, Kashmire et al., 2005, *Methods*, 36, 25-34). In one embodiment only the specificity determining residues from one or more of the CDRs described herein above are transferred to the human antibody framework. In another embodiment only the specificity determining residues from each of the CDRs described herein above are transferred to the human antibody framework.

15 [0034] The preferred framework region for the heavy chain of the CDR-grafted antibody of the present invention is derived from the human sub-group VH3 sequence 1-3 3-07 together with JH4. Accordingly, provided is a neutralising CDR-grafted antibody comprising at least one non-human donor CDR wherein the heavy chain framework region is derived from the human subgroup sequence 1-3 3-07 together with JH4. The sequence of human JH4 is as follows: (YFDY)WGQGTLTVSS. The YFDY motif is part of CDR-H3 and is not part of framework 4 (Ravetch, JV. et al., 1981, *Cell*, 27, 583-591).

20 [0035] The preferred framework region for the light chain of the CDR-grafted antibody of the present invention is derived from the human germline sub-group VK1 sequence 2-1-(1) L4 together with JK1. Accordingly, provided is a neutralising CDR-grafted antibody comprising at least one non-human donor CDR wherein the light chain framework region is derived from the human subgroup sequence VK1 2-1-(1) L4 together with JK1. The JK1 sequence is as follows: (WT)FGQQGTKVEIK. The WT motif is part of CDR-L3 and is not part of framework 4 (Hieter, PA., et al., 1982, *J. Biol. Chem.*, 257, 1516-1522).

25 [0036] Also, in a CDR-grafted antibody of the present disclosure, the framework regions need not have exactly the same sequence as those of the acceptor antibody. For instance, unusual residues may be changed to more frequently-occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found at the same position in the donor antibody (see Reichmann et al., 1998, *Nature*, 332, 323-324). Such changes should be kept to the minimum necessary to recover the affinity of the donor antibody. A protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO 91/09967.

30 [0037] Preferably, in a CDR-grafted antibody molecule of the present disclosure if the acceptor heavy chain has the human VH3 sequence 1-3 3-07 together with JH4, then the acceptor framework regions of the heavy chain comprise, in addition to one or more donor CDRs, a donor residue at at least position 94 (according to Kabat et al.,(supra)). Accordingly, provided is a CDR-grafted antibody, wherein at least the residue at position 94 of the variable domain of the heavy chain is a donor residue.

35 [0038] Preferably, in a CDR-grafted antibody molecule according to the present disclosure if the acceptor light chain has the human sub-group VK1 sequence 2-1-(1) L4 together with JK1, then no donor residues are transferred i.e. only the CDRs are transferred. Accordingly, provided is a CDR-grafted antibody wherein only the CDRs are transferred to the donor framework.

40 [0039] Donor residues are residues from the donor antibody, i.e. the antibody from which the CDRs were originally derived.

45 [0040] In one embodiment, an antibody of the present disclosure comprises a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:9 (gH9).

[0041] In one embodiment, an antibody of the present disclosure comprises a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7 (gL7).

50 [0042] In another embodiment, an antibody of the present disclosure comprises a light chain, wherein the variable domain of the light chain comprises a sequence having at least 95% identity or similarity to the sequence given in SEQ ID NO:7.

[0043] In one embodiment an antibody of the present invention comprises a heavy chain, wherein the variable domain

of the heavy chain comprises the sequence given in SEQ ID NO:9 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7.

5 [0044] In another embodiment of the disclosure, the antibody comprises a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises a sequence having the sequence given in SEQ ID NO:9 and the variable domain of the light chain comprises a sequence having at least 95% identity or similarity to the sequence given in SEQ ID NO:7.

10 [0045] As described herein above, the antibody molecule of the present disclosure may comprise a complete antibody molecule having full length heavy and light chains or a fragment thereof, such as a domain antibody e.g. VH, VL, VHH, Fab, modified Fab, Fab', F(ab')<sub>2</sub>, Fv or scFv fragment.

15 [0046] The constant region domains of the antibody molecule of the present invention, if present, may be selected having regard to the proposed function of the antibody molecule, and in particular the effector functions which may be required. For example, the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains. In particular, human IgG constant region domains may be used, especially of the IgG1 and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required. Alternatively, IgG2 and IgG4 isotypes may be used when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required, e.g. for simply blocking IL-17 activity. For example IgG4 molecules in which the serine at position 241 has been changed to proline as described in Angal et al., Molecular Immunology, 1993, 30 (1), 105-108 may be used. Particularly preferred is the IgG4 constant domain comprising this change.

20 [0047] In one embodiment the antibody heavy chain comprises a CH1 domain and the antibody light chain comprises a CL domain, either kappa or lambda.

25 [0048] In a preferred embodiment the antibody provided by the present invention is a neutralising antibody having specificity for human IL-17A and human IL-17F in which the heavy chain constant region comprises the human IgG4 constant region in which the serine at position 241 has been substituted by proline as described in Angal et al., *supra*. Accordingly, the present invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15.

30 [0049] Preferably, the antibody comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO:15.

35 [0050] In one embodiment an antibody molecule according to the present invention comprises a light chain comprising the sequence given in SEQ ID NO:11.

40 [0051] Preferably, the antibody comprises a light chain, wherein the light chain comprises a sequence having at least 90%, 95% or 98% identity or similarity to the sequence given in SEQ ID NO: 11.

[0052] In one embodiment the present invention provides an antibody in which the heavy chain comprises or consists of the sequence given in SEQ ID NO:15 and the light chain comprises or consists of the sequence given in SEQ ID NO:11.

45 [0053] Also provided by the present disclosure is a specific region or epitope of human IL-17A and/or a specific region or epitope of human IL-17F and/or a specific region or epitope of human IL-17A/F heterodimer which is bound by an antibody provided by the present invention, in particular an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7).

50 [0054] The specific region or epitope of the human IL-17A polypeptide and the specific region or epitope of the human IL-17F polypeptide and the specific region or epitope of the human IL-17A/F heterodimer can be identified by any suitable epitope mapping method known in the art in combination with any one of the antibodies provided by the present invention. Examples of such methods include screening peptides of varying lengths derived from IL-17A and IL-17F for binding to the antibody of the present invention with the smallest fragment that can specifically bind to the antibody containing the sequence of the epitope recognised by the antibody. The IL-17 peptides may be produced synthetically or by proteolytic digestion of the appropriate IL-17 polypeptide. Peptides that bind the antibody can be identified by, for example, mass spectrometric analysis. In another example, NMR spectroscopy can be used to identify the epitope bound by an antibody of the present invention. Once identified, the epitopic fragment which binds an antibody of the present invention can be used, if required, as an immunogen to obtain additional neutralising antibodies which bind the same epitope.

55 [0055] Antibodies which cross-block the binding of an antibody according to the present invention, in particular, an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7), may be similarly useful in neutralising IL-17A and IL-17F activity. Accordingly, the present disclosure also provides a neutralising antibody which binds human IL-17A and human IL-17F, which cross-blocks the binding of any one of the antibodies described above to human IL-17A and/or human IL-17F and/or human IL-17A/F heterodimer and/or is cross-blocked from binding IL-17A and/or IL-17F and/or human IL-17A/F heterodimer by any one of those antibodies. In one embodiment, such an antibody binds to the same epitope as an antibody described herein above.

60 [0056] Cross-blocking antibodies can be identified using any suitable method in the art, for example by using competition ELISA or BIACore where binding of the cross blocking antibody to human IL-17A and/or human IL-17F prevents the binding of an antibody of the present invention or vice versa.

[0057] In one embodiment there is provided a neutralising antibody which binds to human IL-17A and human IL-17F,

which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:9) and whose light chain comprises the sequence gL7 (SEQ ID NO:7) to human IL-17A and to human IL-17F. In one embodiment the cross-blocking antibodies inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

5 [0058] In one embodiment there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:9) and whose light chain comprises the sequence gL7 (SEQ ID NO:7) to human IL-17A and to human IL-17F and to human IL-17A/F heterodimer. In one embodiment the cross-blocking antibodies inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) to IL-17A by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95% and to IL-17A/F heterodimer to IL-17F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

10 [0059] In one embodiment there is provided a neutralising antibody which binds to human IL-17A and human IL-17F, which cross-blocks the binding of an antibody whose heavy chain comprises the sequence gH9 (SEQ ID NO:9) and whose light chain comprises the sequence gL7 (SEQ ID NO:7) to human IL-17A or to human IL-17F or human IL-17A/F heterodimer. In one embodiment the cross-blocking antibodies inhibit the binding of an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) to IL-17A or IL-17F or IL-17A/F by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

15 [0060] Alternatively or in addition, neutralising antibodies may be cross-blocked from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7). Also provided therefore is a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7). In one embodiment the neutralising antibodies are inhibited from binding to human IL-17A and human IL-17F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

20 [0061] In another embodiment there is provided a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A and human IL-17F and IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7). In one embodiment the neutralising antibodies are inhibited from binding to human IL-17A and human IL-17F and human IL-17A/F heterodimer by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

25 [0062] Also provided therefore is a neutralising antibody molecule which binds to human IL-17A and to human IL-17F which is cross-blocked from binding human IL-17A or human IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7). In one embodiment the neutralising antibodies are inhibited from binding to human IL-17A or human IL-17F or human IL-17A/F by an antibody comprising the heavy chain sequence gH9 (SEQ ID NO:9) and the light chain sequence gL7 (SEQ ID NO:7) by greater than 80%, preferably by greater than 85%, more preferably by greater than 90%, even more preferably by greater than 95%.

30 [0063] The antibody molecule of any aspect of the present invention preferably has a high binding affinity, preferably nanomolar, even more preferably picomolar. It will be appreciated that the binding affinity of an antibody according to the present invention for human IL-17A may be different from the binding affinity of the same antibody for human IL-17F and/or the IL-17A/F heterodimer. In one example the antibody molecule of the present invention has an affinity for IL-17A that is greater than its affinity for IL-17F. In one example the antibody molecule of the present invention has an affinity for IL-17A which is at least 10 fold greater than its binding affinity for IL-17F. In one example the antibody molecule of the present invention has an affinity for IL-17A which is at least 50 fold greater than its binding affinity for IL-17F. In one example the antibody molecule of the present invention has an affinity for IL-17A which is at least 100 fold greater than its binding affinity for IL-17F. In one example the antibody molecule of the present invention has an affinity for IL-17F that is greater than its affinity for IL-17A. In one example the antibody molecule of the present invention has an affinity for IL-17A that is the same as its affinity for IL-17F. In one example the antibody molecule of the present invention has a picomolar affinity for IL-17A and a nanomolar affinity for IL-17F. In one example the antibody molecule of the present invention has a nanomolar affinity for IL-17F and a picomolar affinity for IL-17A. In one example the antibody molecule of the present invention has a nanomolar affinity for both IL-17A and IL-17F. In one example the antibody

molecule of the present invention has a picomolar affinity for both IL-17A and IL-17F.

**[0064]** Preferably the antibody molecule of the present invention has a binding affinity for IL-17A of better than 20pM. In one embodiment the antibody of the present invention has an affinity for IL-17A of 16pM.

**[0065]** Preferably the antibody molecule of the present invention has a binding affinity for IL-17F of better than 2 nM. In one embodiment the antibody of the present invention has an affinity for IL-17F of 1.75 nM.

**[0066]** Preferably the antibody molecule of the present invention has a binding affinity for IL-17A/F heterodimer of better than 10nM. In one embodiment the antibody molecule of the present invention has a binding affinity for IL-17A/F heterodimer of better than 500 pM. In one embodiment the antibody molecule of the present invention has a binding affinity for IL-17A/F heterodimer of better than 150 pM. In one embodiment the antibody molecule of the present invention has a binding affinity for IL-17A/F heterodimer of 116pM.

**[0067]** In one embodiment the antibody molecule of the present invention has a binding affinity for cynomolgus IL-17F of better than 2nM. In one embodiment the antibody molecule of the present invention has a binding affinity for cynomolgus IL-17F of 1.03nM.

**[0068]** It will be appreciated that the affinity of antibodies provided by the present invention may be altered using any suitable method known in the art. The present invention therefore also relates to variants of the antibody molecules of the present invention, which have an improved affinity for IL-17A and/or IL-17F. Such variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al., *J. Mol. Biol.*, 254, 392-403, 1995), chain shuffling (Marks et al., *Bio/Technology*, 10, 779-783, 1992), use of mutator strains of *E. coli* (Low et al., *J. Mol. Biol.*, 250, 359-368, 1996), DNA shuffling (Patten et al., *Curr. Opin. Biotechnol.*, 8, 724-733, 1997), phage display (Thompson et al., *J. Mol. Biol.*, 256, 77-88, 1996) and sexual PCR (Crameri et al., *Nature*, 391, 288-291, 1998). Vaughan *et al. (supra)* discusses these methods of affinity maturation.

**[0069]** In one embodiment the antibody molecules of the present invention neutralise IL-17A and IL-17F activity, for example in the *in vitro* assays described in the Examples. In one embodiment the present invention provides a neutralising antibody having specificity for human IL-17A and IL-17F which is capable of inhibiting the activity of 0.8nM human IL-17A by 50% at a concentration of less than 5nM and the activity of 4.2nM IL-17F by 50% at a concentration of less than 12nM said inhibitory activity being measured on the IL-17A or IL-17F induced release of IL-6 from Hela cells. In one embodiment the concentration of antibody which inhibits IL-17A by 50% is less than 3nM. In one embodiment the concentration of antibody which inhibits IL-17F by 50% is less than 11nM. In one embodiment the human IL-17A and human IL-17F used in the assay are recombinant human IL-17A and IL-17F. In one embodiment the neutralising antibody is a humanised or fully human antibody.

**[0070]** If desired an antibody for use in the present invention may be conjugated to one or more effector molecule(s). It will be appreciated that the effector molecule may comprise a single effector molecule or two or more such molecules so linked as to form a single moiety that can be attached to the antibodies of the present invention. Where it is desired to obtain an antibody fragment linked to an effector molecule, this may be prepared by standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or via a coupling agent to the effector molecule. Techniques for conjugating such effector molecules to antibodies are well known in the art (see, Hellstrom et al., *Controlled Drug Delivery*, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, *Immunol. Rev.*, 62:119-58 and Dubowchik et al., 1999, *Pharmacology and Therapeutics*, 83, 67-123). Particular chemical procedures include, for example, those described in WO 93/06231, WO 92/22583, WO 89/00195, WO 89/01476 and WO 03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO 86/01533 and EP0392745.

**[0071]** The term effector molecule as used herein includes, for example, antineoplastic agents, drugs, toxins, biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

**[0072]** Examples of effector molecules may include cytotoxins or cytotoxic agents including any agent that is detrimental to (e.g. kills) cells. Examples include combrestatins, dolastatins, epothilones, staurosporin, maytansinoids, spongistatins, rhizoxin, halichondrins, roridins, hemiasterlins, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

**[0073]** Effector molecules also include, but are not limited to, antimetabolites (e.g. methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g. mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g. daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g. dactinomycin (formerly actinomycin), bleomycin, mithramycin, anthramycin (AMC), calicheamicins or duocarmycins), and anti-mitotic agents (e.g. vincristine and vinblastine).

**[0074]** Other effector molecules may include chelated radionuclides such as  $^{111}\text{In}$  and  $^{90}\text{Y}$ ,  $\text{Lu}^{177}$ , Bismuth  $^{213}$ , Californium  $^{252}$ , Iridium  $^{192}$  and Tungsten  $^{188}$ /Rhenium  $^{188}$ ; or drugs such as but not limited to, alkylphosphocholines, topoisomerase I inhibitors, taxoids and suramin.

**[0075]** Other effector molecules include proteins, peptides and enzymes. Enzymes of interest include, but are not limited to, proteolytic enzymes, hydrolases, lyases, isomerases, transferases. Proteins, polypeptides and peptides of interest include, but are not limited to, immunoglobulins, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, a protein such as insulin, tumour necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor or tissue plasminogen activator, a thrombotic agent or an anti-angiogenic agent, e.g. angiostatin or endostatin, or, a biological response modifier such as a lymphokine, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), nerve growth factor (NGF) or other growth factor and immunoglobulins.

**[0076]** Other effector molecules may include detectable substances useful for example in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliflone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  and  $^{99}\text{Tc}$ .

**[0077]** In another example the effector molecule may increase the half-life of the antibody *in vivo*, and/or reduce immunogenicity of the antibody and/or enhance the delivery of an antibody across an epithelial barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins or albumin binding compounds such as those described in WO05/117984.

**[0078]** Where the effector molecule is a polymer it may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero- polysaccharide.

**[0079]** Particular optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.

**[0080]** Particular examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.

**[0081]** Particular naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof.

**[0082]** "Derivatives" as used herein is intended to include reactive derivatives, for example thiol-selective reactive groups such as maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.

**[0083]** The size of the polymer may be varied as desired, but will generally be in an average molecular weight range from 500Da to 50000Da, preferably from 5000 to 40000Da and more preferably from 20000 to 40000Da. The polymer size may in particular be selected on the basis of the intended use of the product for example ability to localize to certain tissues such as tumors or extend circulating half-life (for review see Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). Thus, for example, where the product is intended to leave the circulation and penetrate tissue, for example for use in the treatment of a tumour, it may be advantageous to use a small molecular weight polymer, for example with a molecular weight of around 5000Da. For applications where the product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 20000Da to 40000Da.

**[0084]** Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 15000Da to about 40000Da.

**[0085]** In one example antibodies for use in the present invention are attached to poly(ethyleneglycol) (PEG) moieties. In one particular example the antibody is an antibody fragment and the PEG molecules may be attached through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods (see for example US 5,219,996; US 5,667,425; WO98/25971). In one example the antibody molecule of the present invention is a modified Fab fragment wherein the modification is the addition to the C-terminal end of its heavy chain one or more amino acids to allow the attachment of an effector molecule. Preferably, the additional amino acids form a modified hinge region containing one or more cysteine residues to which the effector molecule may be attached. Multiple sites can be used to attach two or more PEG molecules.

[0086] Preferably PEG molecules are covalently linked through a thiol group of at least one cysteine residue located in the antibody fragment. Each polymer molecule attached to the modified antibody fragment may be covalently linked to the sulphur atom of a cysteine residue located in the fragment. The covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond. Where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used. An activated polymer may be used as the starting material in the preparation of polymer-modified antibody fragments as described above. The activated polymer may be any polymer containing a thiol reactive group such as an  $\alpha$ -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone or a disulphide. Such starting materials may be obtained commercially (for example from Nektar, formerly Shearwater Polymers Inc., Huntsville, AL, USA) or may be prepared from commercially available starting materials using conventional chemical procedures. Particular PEG molecules include 20K methoxy-PEG-amine (obtainable from Nektar, formerly Shearwater; Rapp Polymere; and SunBio) and M-PEG-SPA (obtainable from Nektar, formerly Shearwater).

[0087] In one embodiment, the antibody is a modified Fab fragment which is PEGylated, i.e. has PEG (poly(ethylene-glycol)) covalently attached thereto, e.g. according to the method disclosed in EP 0948544 [see also "Poly(ethylene-glycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J. Milton Harris (ed), Plenum Press, New York, "Poly(ethylene-glycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S. Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York; Chapman, A. 2002, Advanced Drug Delivery Reviews 2002, 54:531-545]. In one example PEG is attached to a cysteine in the hinge region. In one example, a PEG modified Fab fragment has a maleimide group covalently linked to a single thiol group in a modified hinge region. A lysine residue may be covalently linked to the maleimide group and to each of the amine groups on the lysine residue may be attached a methoxypoly(ethylene-glycol) polymer having a molecular weight of approximately 20,000 Da. The total molecular weight of the PEG attached to the Fab fragment may therefore be approximately 40,000 Da.

[0088] In one embodiment, the present invention provides a neutralising antibody molecule having specificity for human IL-17A and human IL-17F, which is a modified Fab fragment having a heavy chain comprising the sequence given in SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7 and having at the C-terminal end of its heavy chain a modified hinge region containing at least one cysteine residue to which an effector molecule is attached. Preferably the effector molecule is PEG and is attached using the methods described in (WO98/25971 and WO2004072116) whereby a lysyl-maleimide group is attached to the cysteine residue at the C-terminal end of the heavy chain, and each amino group of the lysyl residue has covalently linked to it a methoxypoly(ethylene-glycol) residue having a molecular weight of about 20,000 Da. The total molecular weight of the PEG attached to the antibody is therefore approximately 40,000Da.

[0089] In another example effector molecules may be attached to antibody fragments using the methods described in International patent applications WO2005/003169, WO2005/003170 and WO2005/003171.

[0090] The present invention also provides an isolated DNA sequence encoding the heavy and light chains of an antibody molecule of the present invention. The DNA sequence of the present invention may comprise synthetic DNA, for instance produced by chemical processing, cDNA, genomic DNA or any combination thereof.

[0091] DNA sequences which encode an antibody molecule of the present invention can be obtained by methods well known to those skilled in the art. For example, DNA sequences coding for part or all of the antibody heavy and light chains may be synthesised as desired from the determined DNA sequences or on the basis of the corresponding amino acid sequences.

[0092] DNA coding for acceptor framework sequences is widely available to those skilled in the art and can be readily synthesised on the basis of their known amino acid sequences.

[0093] Standard techniques of molecular biology may be used to prepare DNA sequences coding for the antibody molecule of the present invention. Desired DNA sequences may be synthesised completely or in part using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as appropriate.

[0094] Examples of suitable sequences are provided in SEQ ID NO:8; SEQ ID NO:10; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 17 and SEQ ID NO: 18. Nucleotides 1-57 in SEQ ID NO 18 and 1-60 in SEQ ID NO 14 encode the signal peptide sequence from mouse antibody B72.3 (Whittle et al., 1987, Protein Eng. 1(6) 499-505.) which is cleaved to give a neutralising antibody molecule of the present invention.

[0095] The present invention also relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. Accordingly, provided is a cloning or expression vector comprising one or more DNA sequences encoding an antibody of the present invention. Preferably, the cloning or expression vector comprises two DNA sequences, encoding the light chain and the heavy chain of the antibody molecule of the present invention, respectively. Preferably, a vector according to the present invention comprises the sequences given in SEQ ID NO:14 and SEQ ID NO:18. Nucleotides 1-57 in SEQ ID NO 18 and 1-60 in SEQ ID NO 14 encode the signal peptide sequence from mouse antibody B72.3 (residues 1-19 in SEQ ID NO: 16 and 1-20 in SEQ ID NO:12 respectively) which is most preferably

cleaved to give a neutralising antibody molecule of the present invention.

[0096] General methods by which the vectors may be constructed, transfection methods and culture methods are well known to those skilled in the art. In this respect, reference is made to "Current Protocols in Molecular Biology", 1999, F. M. Ausubel (ed), Wiley Interscience, New York and the Maniatis Manual produced by Cold Spring Harbor Publishing.

[0097] Also provided is a host cell comprising one or more cloning or expression vectors comprising one or more DNA sequences encoding an antibody of the present invention. Any suitable host cell/vector system may be used for expression of the DNA sequences encoding the antibody molecule of the present invention. Bacterial, for example *E. coli*, and other microbial systems may be used or eukaryotic, for example mammalian, host cell expression systems may also be used. Suitable mammalian host cells include CHO, myeloma or hybridoma cells.

[0098] The present invention also provides a process for the production of an antibody molecule according to the present invention comprising culturing a host cell containing a vector of the present invention under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.

[0099] The antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host cells. For production of products comprising both heavy and light chains, the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.

[0100] As the antibodies of the present invention are useful in the treatment and/or prophylaxis of a pathological condition, the present invention also provides a pharmaceutical or diagnostic composition comprising an antibody molecule of the present invention in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. Accordingly, provided is the use of an antibody according to the present invention for the manufacture of a medicament. The composition will usually be supplied as part of a sterile, pharmaceutical composition that will normally include a pharmaceutically acceptable carrier. A pharmaceutical composition of the present invention may additionally comprise a pharmaceutically-acceptable adjuvant.

[0101] The present invention also provides a process for preparation of a pharmaceutical or diagnostic composition comprising adding and mixing the antibody molecule of the present invention together with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

[0102] The antibody molecule may be the sole active ingredient in the pharmaceutical or diagnostic composition or may be accompanied by other active ingredients including other antibody ingredients, for example anti-TNF, anti- IL-1 $\beta$ , anti-T cell, anti-IFNy or anti-LPS antibodies, or non-antibody ingredients such as xanthines.

[0103] The pharmaceutical compositions preferably comprise a therapeutically effective amount of the antibody of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any antibody, the therapeutically effective amount can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0104] The precise therapeutically effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, a therapeutically effective amount will be from 0.01 mg/kg to 50 mg/kg, preferably 0.1 mg/kg to 20 mg/kg. Pharmaceutical compositions may be conveniently presented in unit dose forms containing a predetermined amount of an active agent of the invention per dose.

[0105] Compositions may be administered individually to a patient or may be administered in combination (e.g. simultaneously, sequentially or separately) with other agents, drugs or hormones.

[0106] The dose at which the antibody molecule of the present invention is administered depends on the nature of the condition to be treated, the extent of the inflammation present and on whether the antibody molecule is being used prophylactically or to treat an existing condition.

[0107] The frequency of dose will depend on the half-life of the antibody molecule and the duration of its effect. If the antibody molecule has a short half-life (e.g. 2 to 10 hours) it may be necessary to give one or more doses per day. Alternatively, if the antibody molecule has a long half life (e.g. 2 to 15 days) it may only be necessary to give a dosage once per day, once per week or even once every 1 or 2 months.

[0108] The pharmaceutically acceptable carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should not be toxic. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

[0109] Pharmaceutically acceptable salts can be used, for example mineral acid salts, such as hydrochlorides, hyd-

robromides, phosphates and sulphates, or salts of organic acids, such as acetates, propionates, malonates and benzoates.

**[0110]** Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents or pH buffering substances, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by the patient.

**[0111]** Preferred forms for administration include forms suitable for parenteral administration, e.g. by injection or infusion, for example by bolus injection or continuous infusion. Where the product is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents, such as suspending, preservative, stabilising and/or dispersing agents. Alternatively, the antibody molecule may be in dry form, for reconstitution before use with an appropriate sterile liquid.

**[0112]** Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals. However, it is preferred that the compositions are adapted for administration to human subjects.

**[0113]** The pharmaceutical compositions of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous (for example, see WO 98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal routes. Hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

**[0114]** Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

**[0115]** It will be appreciated that the active ingredient in the composition will be an antibody molecule. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation but which release the antibody once it has been absorbed from the gastrointestinal tract.

**[0116]** A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, N.J. 1991).

**[0117]** It is also envisaged that the antibody of the present invention will be administered by use of gene therapy. In order to achieve this, DNA sequences encoding the heavy and light chains of the antibody molecule under the control of appropriate DNA components are introduced into a patient such that the antibody chains are expressed from the DNA sequences and assembled *in situ*.

**[0118]** The present invention also provides an antibody molecule for use in the control of inflammatory diseases. Preferably, the antibody molecule can be used to reduce the inflammatory process or to prevent the inflammatory process.

**[0119]** The present invention also provides the antibody molecule of the present invention for use in the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F or is associated with an increased level of IL-17A and/or IL-17F. Preferably, the pathological condition is selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis, rheumatoid arthritis, asthma, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, inflammatory bowel disease, Ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme arthritis, meningoencephalitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis and Guillain-Barr syndrome, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, cancer (both solid tumours such as melanomas, hepatoblastomas, sarcomas, squamous cell carcinomas, transitional cell cancers, ovarian cancers and hematologic malignancies and in particular acute myelogenous leukaemia, chronic myelogenous leukemia, gastric cancer and colon cancer), heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, periodontitis and hypochlorhydria.

**[0120]** The present invention also provides an antibody molecule according to the present invention for use in the treatment or prophylaxis of pain.

**[0121]** The present invention further provides the use of an antibody molecule according to the present invention in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F or associated with an increased level of IL-17A and/or IL-17F. Preferably the pathological disorder is rheumatoid arthritis or multiple sclerosis.

**[0122]** The present invention further provides the use of an antibody molecule according to the present invention in the manufacture of a medicament for the treatment or prophylaxis of pain.

**[0123]** An antibody molecule of the present invention may be utilised in any therapy where it is desired to reduce the effects of IL-17A and/or IL-17F in the human or animal body. IL-17 A and/or IL-17F may be circulating in the body or

may be present in an undesirably high level localised at a particular site in the body, for example a site of inflammation.

**[0124]** An antibody molecule according to the present invention is preferably used for the control of inflammatory disease, autoimmune disease or cancer.

**[0125]** The present invention also provides a method of treating human or animal subjects suffering from or at risk of a disorder mediated by IL-17A and/or IL-17F, the method comprising administering to the subject an effective amount of an antibody molecule of the present invention.

**[0126]** An antibody molecule according to the present invention may also be used in diagnosis, for example in the *in vivo* diagnosis and imaging of disease states involving IL-17A and/or IL-17F.

**[0127]** The present invention is further described by way of illustration only in the following examples, which refer to the accompanying Figures, in which:

Figure: 1

- a) Light chain V region of antibody CA028\_0496 (SEQ ID NO:7)
- b) Heavy chain V region of antibody CA028\_0496 (SEQ ID NO:9)
- c) CDRH1 (SEQ ID NO:1), CDRH2 (SEQ ID NO:2), CDRH3 (SEQ ID NO:3), CDRL1 (SEQ ID NO:4), CDRL2 (SEQ ID NO:5), CDRL3 (SEQ ID NO:6) of antibody CA028\_496.
- d) Light chain of antibody CA028\_496 (SEQ ID NO:11).
- e) Heavy chain of antibody CA028\_496 (SEQ ID NO:15).
- f) DNA encoding light chain of antibody CA028\_496 including signal sequence (SEQ ID NO:14).
- g) DNA encoding heavy chain of antibody CA028\_496 including signal sequence (SEQ ID NO:18)

Figure 2 a) The effect of antibody CA028\_0496 (designated Ab#496 in legend) on human IL-17 induced IL-6 production from Hela cells. b) The effect of antibody CA028\_0496 (designated Ab#496 in legend) on human IL-17F induced IL-6 production from Hela cells

#### *DNA manipulations and general methods*

**[0128]** *E. coli* strain INV $\alpha$ F' (Invitrogen) was used for transformation and routine culture growth. DNA restriction and modification enzymes were obtained from Roche Diagnostics Ltd. and New England Biolabs. Plasmid preparations were performed using Maxi Plasmid purification kits (QIAGEN, catalogue No. 12165). DNA sequencing reactions were performed using the ABI Prism Big Dye terminator sequencing kit (catalogue No. 4304149) and run on an ABI 3100 automated sequencer (Applied Biosystems). Data was analysed using the program AutoAssembler (Applied Biosystems). Oligo-nucleotides were obtained from Invitrogen. The concentration of IgG was determined using IgG assembly ELISA.

#### IL-17 isoforms

**[0129]** Recombinant IL-17A and IL-17F were purchased from R&D Systems.

**[0130]** Recombinant IL-17A/F heterodimer was produced by linking IL-17A and IL-17F using a GS linker. The heterodimer had the following sequence (SEQ ID NO:19)

**[0131]** MGITIPRNP GCPNSEDKNFPRTVMVNLNIHNRNTNPKRSSDYYNRSTSPWNLHRN  
EDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEK  
ILSVGCTCVPIVHHVAGGGGGGGGGGGGGGGGGSRKIPKVGH TFFQKPESCP  
50 PVPGGSMKLDIGIINENQRVMSMRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNL  
GCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLTVGCTCVTPVIHHV Q

Recombinant cynomolgus IL-17F (SEQ ID NO:20)

**[0132]** MRKIPKVGH TFFQKPESCPVPEGSMKLDTGIIENQRVMSMRNIESRSTSPWNYTVTWDPN  
RYPSEVVQAQCKHLGCINAQGKEDISMNSVPIQQETLVRRKHQGCSVSFQLEKVLTVGCT CVTPVIHHVQ

**[0133]** The DNA sequence encoding IL-17A/F heterodimer was chemically synthesised by Entelechon GmbH and was subcloned into pET43.1a at the NdeI/Xhol sites.

The DNA sequence encoding cyno L-17F was amplified by PCR using primers that introduced NdeI and Xhol restriction sites. The PCR products were ligated into pCR4Blunt-TOPO and sequence verified before digestion and ligation into pET43.1a at the NdeI/Xhol sites.

[0134] pET43.1a DNA encoding IL-17 isoforms was used to transfet BL21(DE3) cells and selected carbenicillin-resistant clones were grown at 37°C overnight in 2TY broth containing 2% glucose and 50/µg/ml carbenicillin. The cultures were then diluted and grown in the same medium to an OD<sub>600</sub> of 0.5-0.7, induced with 1mM IPTG and grown at 37°C for a further 4-5 hours.

[0135] Cells were harvested by centrifugation and inclusion bodies prepared from the cells. Inclusion bodies were solubilised in 50mM Tris-HCl, 5M guanidinium hydrochloride, 50mM NaCl, 1mM EDTA, 2mM reduced glutathione, 0.2mM oxidised glutathione, pH 8.5. IL-17 protein was refolded by dropwise addition of the solubilised protein to the above buffer without guanidinium hydrochloride, with vigorous stirring. The final volume was chosen such that the final protein concentration was no more than 0.1mg/ml.

[0136] The refolded protein solution was concentrated if required, before buffer exchange with 10mM MES pH6. The protein was then applied to a column of Sepharose SP HP equilibrated with 20mM MES pH6. Protein was eluted with a linear gradient of 0-500mM NaCl in MES pH6 over 10 column volumes. For IL-17F the gradient was extended to 600mM NaCl. In order to further purify IL-17, the relevant fraction from the Sepharose SP HP column were pooled, concentrated and diluted with 20mM CAPSO (pH10) and applied to a Mono Q column equilibrated with 20mM CAPSO. Protein was eluted with a linear gradient of 0-250mM NaCl in 20mM CAPSO over 20 column volumes. Fractions containing IL-17 were pooled and neutralised using 1M MES pH6.

#### Example 1: Production of a neutralising anti-IL-17 antibody

[0137] Female Sprague Dawly rats were immunised with recombinant human IL-17 (purchased from R & D systems). Rats received four immunisations of 20µg IL-17 in 100µl Freund's adjuvant. Antibody 225 which binds human IL-17 was isolated using the methods described in WO04/051268. Genes for the heavy chain variable domain (VH) and light chain variable domain (VL) of antibody 225 were isolated and sequenced following cloning via reverse transcription PCR.

[0138] A series of humanised VL and VH regions were designed using human V-region acceptor frameworks and by varying the number of donor residues in the framework regions. Eight grafted VL regions (gL1-8) and 9 grafted VH regions (gH1-9) were designed and genes were built by oligonucleotide assembly and PCR mutagenesis.

[0139] The light chain grafted sequences were sub-cloned into the human light chain expression vector pKH10. 1 which contains the DNA encoding the human C-Kappa constant region (Km3 allotype). The heavy chain grafted sequences were sub-cloned into the human gamma-4 expression vector pVhg4P FL, which contains the DNA encoding the human gamma-4 constant region containing the hinge stabilising mutation S241P (Angal *et al.*, *supra*). Plasmids were co-transfected into CHO cells and the antibodies produced screened for activity in IL-17 binding and neutralisation assays. Transfections of CHO cells were performed using the Lipofectamine™ 2000 procedure according to manufacturer's instructions (InVitrogen, catalogue No. 11668).

[0140] The most optimal graft based on expression, affinity and neutralisation potency (gL7gH9) was selected and named CA028\_0496. The V region sequences of this antibody are shown in Figure 1 (a) and (b) and in SEQ ID NOS: 7 and 9 for the light chain (gL7) and heavy chains (gH9) respectively.

[0141] The heavy chain acceptor framework is the human germline sequence VH3 1-3 3-07 with framework 4 coming from this portion of the human JH-region germline JH4. The light chain acceptor framework is the human germline sequence VK1 2-1-(1) L4, with framework 4 coming from this portion of the human JK-region germline JK1.

#### Example 2: Antibody CA028 0496 neutralises IL-17 and IL-17F and IL-17A/F heterodimer

##### Hela cells

[0142] The potency of antibody CA028\_0496 against human recombinant IL-17 and human recombinant IL-17F in Hela cells was tested and compared to antibody CDP435 (WO06/054059). Hela cells were obtained from the cell bank at ATCC (ATCC CCL-2). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum, penicillin, gentamycin and glutamine. 1x10<sup>4</sup> cells were plated out into 96 well flat bottomed tissue culture plates. Cells were incubated overnight and washed once in assay buffer. Either human IL-17A (25ng ml<sup>-1</sup>) or human IL-17F (125ng ml<sup>-1</sup>) was incubated in the presence of a fixed concentration of human TNF- $\alpha$  this mixture was preincubated with antibody CA028\_0496 or antibody CDP435. Cytokine plus antibody was then added to the Hela cells which were incubated overnight. The production of IL-6 in the cell culture supernatant was proportionate to the amount of IL-17A/IL-17F added to the cells. Human IL-6 levels were measured by ELISA and quantified by comparison with known standard concentrations of human IL-6.

[0143] The data (Figures 2a and 2b) indicates that antibody CA028\_0496 potently neutralised human recombinant

5 IL-17A and also had some activity against human IL-17F. The data from these experiments indicated that antibody CA028\_0496 gave an IC<sub>50</sub> of 43/nM against human recombinant IL-17 (25nM ml<sup>-1</sup>) and 1477nM/ml against recombinant IL-17F (125nM ml<sup>-1</sup>). Accordingly, antibody CA028\_0496 gave an IC<sub>50</sub> of 0.29M against human recombinant IL-17 (0.78nM) and 10.18nM against human recombinant IL-17F (4.16nM) in this assay (calculation based on per IgG assuming a molecular weight of 145,000 as an average IgG4 and assuming that IL-17A and IL-17F are dimers).

#### Human microglia cells

10 [0144] Human microglia cells (TCS Cellworks) were plated out in a flat bottom 96-well plate at 5,000 cells per well in a total volume of 100  $\mu$ l and left for 24 hours to attach to the plastic. At this time titrations (5, 1, 0.2 and 0.04  $\mu$ g/ml) of human recombinant IL-17A, human recombinant IL-17F, cynomolgus recombinant IL-17F and human recombinant IL-17A/F heterodimer in the presence and absence of 10 ng/ml human recombinant TNF $\alpha$  were added to wells in triplicate. Control wells contained no stimulation, IL-17A alone (100ng/ml), TNF $\alpha$  alone and IL-17A and TNF $\alpha$  together. All cytokines were added in a total volume of 110  $\mu$ l/well, making the total well volume 210  $\mu$ l. In experiments involving antibodies, cells were plated out in the same way. After 24 hours antibodies and cytokines were added at the same time to give the stated final concentrations in a total final volume of 200  $\mu$ l.

15 [0145] After a further 24 hours incubation at 37°C, supernatants were harvested and frozen at -20°C until analysis. For analysis, supernatants were diluted 1/10 and measured for IL-6 using a human IL-6 MSD kit, according to manufacturer's instructions.

20 [0146] All isoforms of IL-17 tested were found to be active in the assay, particularly in the presence of TNF $\alpha$ .

[0147] The potency of antibody CA028\_0496 against human recombinant IL-17A and human recombinant IL-17F, cynomolgus recombinant IL-17F and human recombinant IL-17A/F heterodimer in human microglia cells was tested in the presence of TNF $\alpha$  and compared to a control antibody and an IL-17A specific antibody using the method described above.

25 [0148] The control antibody had no effect on the activity of any of the cytokines tested.

[0149] Antibody CA028\_0496 had inhibitory activity against all three cytokines IL-17, IL-17F and IL-17A/F, including cynomolgus IL-17F while the IL-17A specific antibody only had inhibitory activity against IL-17A and IL-17A/F heterodimer.

#### Example 3: Affinity of antibody CA028 0496 (human IgG4 constant regions) for IL-17A and IL-17F

30 [0150] BIA (Biamolecular Interaction Analysis) was performed using a Biacore 3000 (Biacore AB). All experiments were performed at 25 °C. Affinipure Fc Fragment goat anti-human IgG, Fc fragment specific (Jackson ImmunoResearch) was immobilised on a CM5 Sensor Chip via amine coupling chemistry to a capture level of  $\approx$ 6000 response units (RUs). HBS-EP buffer (10mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005 % Surfactant P20, Biacore AB) was used as the running buffer with a flow rate of 10  $\mu$ l/min. A 10  $\mu$ l injection of antibody CA028\_0496 (1.81mg/ml) was used for capture by the immobilised anti-human IgG-Fc. Human IL-17A and IL-17 isoforms were titrated over the captured CA028\_0496 at doubling dilutions from 50nM to sub nM at a flow rate of 30  $\mu$ L/min. The surface was regenerated by a 30  $\mu$ L injections of 40 mM HCl, followed by one 5  $\mu$ L injection of 5 mM NaOH.

35 [0151] Background subtraction binding curves were double referenced and analysed using the BIAevaluation software (version 3.2) following standard procedures. Kinetic parameters were determined from the fitting algorithm.

40 [0152] The affinity value determined for antibody CA028\_0496 binding IL-17A was 16 pM and 1750pM for IL-17F. Antibody CA028\_0496 did not bind to the other IL-17 isoforms (IL-17 B, C, D and E). Antibody CA028\_0496 therefore specifically binds IL-17A and IL-17F.

#### Example 4: Affinity of antibody CA028 0496 (murine IgG1 constant regions) for IL-17A, cynomolgus IL-17F and IL-17A/F heterodimer

45 [0153] BIA (Biamolecular Interaction Analysis) was performed using a Biacore 3000 (Biacore AB). All experiments were performed at 25 °C. Affinipure F(ab')<sub>2</sub> fragment goat anti-mouse IgG, Fc fragment specific (Jackson ImmunoResearch) was immobilised on a CM5 Sensor Chip (Biacore AB) via amine coupling chemistry to a capture level of  $\approx$ 6000 response units (RUs). HBS-EP buffer (10mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005 % Surfactant P20, Biacore AB) was used as the running buffer with a flow rate of 10  $\mu$ L/min. A 10  $\mu$ L injection of antibody CA028\_0496 at 4ug/ml was used for capture by the immobilised anti-mouse IgG, Fc. Human IL-17A, cyno IL-17F and heterodimerA/F were titrated over the captured CA028\_0496 at doubling dilutions from 25nM to sub nM at a flow rate of 30  $\mu$ L/min. The surface was regenerated at a flowrate of 10uL/min by a 10  $\mu$ L injection of 40 mM HCl, followed by a 5  $\mu$ L injection of 5 mM NaOH.

50 [0154] Double referenced background subtracted binding curves were analysed using the BIAevaluation software (version 3.2) following standard procedures. Kinetic parameters were determined from the fitting algorithm.

[0155] Antibody CA028\_0496 had an affinity of 21pM for IL-17A, 116pM for IL-17A/F heterodimer and 1030pM for cynomolgus IL-17F.

[0156] It will of course be understood that the present invention has been described by way of example only, is in no way meant to be limiting, and that modifications of detail can be made within the scope of the claims hereinafter.

5

## SEQUENCE LISTING

## [0157]

10 <110> UCB PHARMA S.A. Adams, Ralph Popplewell, Andrew Rapecki, Stephen

<120> Antibody molecules which bind IL-17A and IL-17F

<130> G0035-WO01

15

<160> 20

<170> PatentIn version 3.3

20 &lt;210&gt; 1

<211> 10

<212> PRT

<213> Rattus rattus

25 &lt;400&gt; 1

Gly	Phe	Thr	Phe	Ser	Asp	Tyr	Asn	Met	Ala
1								10	

30

<210> 2

<211> 17

<212> PRT

<213> Artificial

35

<220>

<223> CDRH2

<400> 2

40

Thr	Ile	Thr	Tyr	Glu	Gly	Arg	Asn	Thr	Tyr	Tyr	Arg	Asp	Ser	Val	Lys
1					5									10	15

45

Gly

<210> 3

<211> 16

<212> PRT

50

<213> Artificial

<220>

<223> CDRH3

55

<400> 3

**EP 2 076 539 B1**

Pro Pro Gln Tyr Tyr Glu Gly Ser Ile Tyr Arg Leu Trp Phe Ala His  
1 5 10 15

5 <210> 4  
<211> 11  
<212> PRT  
<213> Artificial

10 <220>  
<223> CDRL1  
  
<400> 4

15 Arg Ala Asp Glu Ser Val Thr Thr Leu Met His  
1 5 10

20 <210> 5  
<211> 7  
<212> PRT  
<213> Rattus rattus

25 <400> 5

Leu Val Ser Asn Arg Glu Ser  
1 5

30 <210> 6  
<211> 9  
<212> PRT  
<213> Rattus rattus

35 <400> 6

Gln Gln Thr Trp Ser Asp Pro Trp Thr  
1 5

40 <210> 7  
<211> 108  
<212> PRT  
<213> Artificial

45 <220>  
<223> gL7  
  
<400> 7

50  
  
  
  
  
55

**EP 2 076 539 B1**

Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Thr Thr Leu  
20 25 30

10 Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile  
35 40 45

Tyr Leu Val Ser Asn Arg Glu Ser Gly Val Pro Ser Arg Phe Ser Gly  
15 50 55 60

20 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

25 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp Ser Asp Pro Trp  
85 90 95

25 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg  
100 105

30 <210> 8  
<211> 324  
<212> DNA  
<213> Artificial

35 <220>  
<223> gL7

<400> 8

40 gccatccagc tgacccagag cccttcctct ctcagcgcca gtgtcggaga cagagtgact 60  
attacctgca gggctgacga aagcgtgacc acattgatgc actggtagcca acagaaggct 120  
ggcaaagccc ccaagctcct gatctatctg gtttccaatc gggagtctgg agtccccagc 180  
45 aggttcagcg gcagtgggtc tggaaactgac tttaccctga caatctcctc actccagccc 240  
gaagatttcg ccacctacta ttgccagcag acttggagcgc acccttggac atttggacag 300  
ggcacaaaaag tggagatcaa gcgt 324

50 <210> 9  
<211> 125  
<212> PRT  
<213> Artificial

55 <220>  
<223> gH9

&lt;400&gt; 9

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5					10				15	

5

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Tyr
					20					25				30	

10

Asn	Met	Ala	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
					35			40				45			

15

Ala	Thr	Ile	Thr	Tyr	Glu	Gly	Arg	Asn	Thr	Tyr	Tyr	Arg	Asp	Ser	Val
					50			55				60			

20

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr
					65		70			75			80		

Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85			90					95		

25

Ala	Ser	Pro	Pro	Gln	Tyr	Tyr	Glu	Gly	Ser	Ile	Tyr	Arg	Leu	Trp	Phe
					100			105				110			

30

Ala	His	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser			
					115			120			125				

&lt;210&gt; 10

&lt;211&gt; 375

35

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; gH9

40

&lt;400&gt; 10

gaggttcagc tcgttgaatc cggaggcgga ctctgtgcagc ctgggggctc cttgcggctg 60

45

agctgcgtg ccagtggctt cactttcagc gattacaata tggcctgggt gcgccaggcc 120

ccaggcaagg gtctggagtg ggtggccaca attacctatg agggcagaaa cacttattac 180

cgggattcag taaaaggcg atttaccatc agcaggata atgcaaagaa cagtctgtac 240

50

ctgcagatga actctctgag agctgaggac accgctgtct actattgtgc aagcccaccc 300

cagtactatg agggctcaat ctacagattg tggtttgcac attggggccaa gggAACACTG 360

55

gtgaccgtct cgagc 375

&lt;210&gt; 11

&lt;211&gt; 214

**EP 2 076 539 B1**

<212> PRT

<213> Artificial

<220>

5 <223> GL7+constant domain

<400> 11

10 Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser Val Thr Thr Leu

15

20

25

30

35

40

45

50

55

	20	25	30
5	Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45		
10	Tyr Leu Val Ser Asn Arg Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60		
	Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80		
15	Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp Ser Asp Pro Trp 85 90 95		
20	Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110		
25	Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125		
	Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140		
30	Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160		
35	Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175		
40	Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190		
	Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205		
45	Phe Asn Arg Gly Glu Cys 210		
50	<210> 12 <211> 234 <212> PRT <213> Artificial		
	<220>		
55	<223> Signal+gL7+constant domain		

EP 2 076 539 B1

<400> 12

Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr  
1 5 10 15

5

Asp Ala Arg Cys Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser  
20 25 30

10

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Asp Glu Ser  
35 40 45

15

Val Thr Thr Leu Met His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro  
50 55 60

20

Lys Leu Leu Ile Tyr Leu Val Ser Asn Arg Glu Ser Gly Val Pro Ser  
65 70 75 80

25

Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser  
85 90 95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Trp  
100 105 110

30

Ser Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg  
115 120 125

35

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln  
130 135 140

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr  
145 150 155 160

40

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser  
165 170 175

45

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr  
180 185 190

50

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys  
195 200 205

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro  
210 215 220

55

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

225

230

5                   <210> 13  
 <211> 645  
 <212> DNA  
 <213> Artificial

10                  <220>  
 <223> gL7+constant domain

15                  <400> 13

15    gccatccagc tgacccagag cccttcctct ctcagcgcca gtgtcggaga cagagtgact    60  
 attacctgca gggctgacga aagcgtgacc acattgatgc actggtagca acagaaggct    120  
 ggc当地  
 20    ggcaaaggccc ccaagctcct gatctatctg gtttccaatc gggagctgg agtccccagc    180  
 aggttcagcg gcagtggtc tggaaactgac tttaccctga caatctcctc actccagccc    240  
 gaagatttcg ccacctacta ttgccagcag acttggagcg acccttggac atttggacag    300  
 ggc当地  
 25    tctgatgagc agttgaaatc tggaaactgcc tctgttgtgt gcctgctgaa taacttctat    360  
 cccagagagg ccaaagtaca gtggaaaggta gataacgccc tccaaatcggg taactcccag    420  
 30    gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg    480  
 ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcaggc    540  
 ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag                   600  
 35  
 <210> 14  
 <211> 705  
 <212> DNA  
 <213> Artificial

40                  <220>  
 <223> signal+gL7+constant domain

45                  <400> 14

50

55

**EP 2 076 539 B1**

atgtcagttc ccacacaggt gctgggcctg cttctgttgt ggctcaccga tgcttaggtgt 60  
5 gccatccagc tgacccagag cccttcctct ctcagcgcca gtgtcggaga cagagtgact 120  
attacctgca gggctgacga aagcgtgacc acattgatgc actggatcca acagaaggct 180  
ggcaaagccc ccaagctcct gatctatctg gtttccaatc gggagtctgg agtcccagc 240  
10 aggttcagcg gcagtgggtc tggaactgac tttaccctga caatctcctc actccagccc 300  
gaagatttcg ccacctacta ttgccagcag acttggagcg acccttggac atttggacag 360  
ggcacaaaag tggagatcaa gcgtacggta gcggcccat ctgtcttcat cttccgc当地 420  
15 tctgatgagc agttgaaatc tggaactgccc tctgttgtgt gcctgctgaa taacttctat 480  
cccagagagg ccaaagtaca gtggaagggtg gataacgccc tccaaatcggg taactcccag 540  
20 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600  
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtca ccatcaggc当地 660  
ctgagctcgc ccgtcacaag gagcttcaac aggggagagt gttag 705  
25  
<210> 15  
<211> 452  
<212> PRT  
<213> Artificial  
30  
<220>  
<223> gH9+constant domain  
35  
<400> 15

40

45

50

55

**EP 2 076 539 B1**

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr  
20 25 30

10 Asn Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45

15 Ala Thr Ile Thr Tyr Glu Gly Arg Asn Thr Tyr Tyr Arg Asp Ser Val  
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
65 70 75 80

20 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

25 Ala Ser Pro Pro Gln Tyr Tyr Glu Gly Ser Ile Tyr Arg Leu Trp Phe  
100 105 110

30 Ala His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr  
115 120 125

Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser  
130 135 140

35 Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu  
145 150 155 160

40

45

50

55

**EP 2 076 539 B1**

Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His  
165 170 175

5 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser  
180 185 190

10 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys  
195 200 205

15 Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu  
210 215 220

20 Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu  
225 230 235 240

25 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu  
245 250 255

30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser  
260 265 270

35 Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu  
275 280 285

40 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr  
290 295 300

45 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn  
305 310 315 320

50 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser  
325 330 335

55 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln  
340 345 350

60 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val  
355 360 365

65 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val  
370 375 380

70 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro  
385 390 395 400

EP 2 076 539 B1

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr  
405 410 415

5 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val  
420 425 430

10 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu  
435 440 445

Ser Leu Gly Lys  
450

15 <210> 16  
<211> 471  
<212> PRT  
<213> Artificial

20 <220>  
<223> signal+gH9+constant domain

25 <400> 16

Met Glu Trp Ser Trp Val Phe Leu Phe Phe Leu Ser Val Thr Thr Gly  
1 5 10 15

30 Val His Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln  
20 25 30

35 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe  
35 40 45

40 Ser Asp Tyr Asn Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu  
50 55 60

65 Glu Trp Val Ala Thr Ile Thr Tyr Glu Gly Arg Asn Thr Tyr Tyr Arg  
65 70 75 80

45 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn  
85 90 95

50 Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val  
100 105 110

55 Tyr Tyr Cys Ala Ser Pro Pro Gln Tyr Tyr Glu Gly Ser Ile Tyr Arg  
115 120 125

**EP 2 076 539 B1**

Leu Trp Phe Ala His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
130 135 140

5 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg  
145 150 155 160

10 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
165 170 175

15 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
180 185 190

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
195 200 205

20 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr  
210 215 220

25 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys  
225 230 235 240

30 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro  
245 250 255

Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys  
260 265 270

35 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val  
275 280 285

40 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp  
290 295 300

45 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe  
305 310 315 320

50 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp  
325 330 335

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu  
340 345 350

55 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg  
355 360 365

**EP 2 076 539 B1**

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys  
370 375 380

5 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp  
385 390 395 400

10 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys  
405 410 415

15 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser  
420 425 430

20 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser  
435 440 445

25 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser  
450 455 460

30 Leu Ser Leu Ser Leu Gly Lys  
465 470

<210> 17

<211> 1963

<212> DNA

30 <213> Artificial

<220>

<223> gH9+constant domain

35 <400> 17

40 gaggttcagc tcgttgaatc cggaggcgga ctcgtgcagc ctgggggctc cttgcggctg 60  
agctgcgctg ccagtggctt cactttcagc gattacaata tggcctgggt gcgccaggcc 120  
ccaggcaagg gtctggagtg ggtggccaca attacctatg agggcagaaa cacttattac 180  
cgggattcag taaaaggcg atttaccatc agcagggata atgcaaagaa cagtctgtac 240  
45 ctgcagatga actctctgag agctgaggac accgctgtct actattgtgc aagcccaccc 300  
cagtactatg agggctcaat ctacagattg tggtttgc 360  
50 cttggggcc ggtgaccgtct cgagcgcttc taaaagggc ccatccgtct tccccctggc gccctgctcc 420  
aggagcacct ccgagagcac agccgcctg ggctgcctgg tcaaggacta cttcccccggaa 480  
ccgggtgacgg tgcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttcccccggct 540  
55 gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc 600

	ttgggcacga agacctacac ctgcaacgta gatcacaaggc ccagcaacac caagggtggac	660
	aagagagttg gtgagaggcc agcacaggga gggagggtgt ctgctggaag ccaggctcag	720
5	ccctcctgcc tggacgcacc ccggctgtgc agccccagcc cagggcagca aggcattgccc	780
	catctgtctc ctcacccgga ggcctctgac cacccactc atgcccaggg agagggttctt	840
10	ctggattttt ccaccaggct ccgggcagcc acaggctgga tgcccctacc ccaggccctg	900
	cgcatacagg ggcaggtgtc gcgcctcagac ctgccaagag ccatatccgg gaggaccctg	960
	cccctgacct aagcccaccc caaaggccaa actctccact ccctcagctc agacacccctc	1020
15	tctcctccca gatctgagta actcccaatc ttctctctgc agagtccaaa tatggtcccc	1080
	catgcccacc atgcccaggta aagccaaaccc aggccctcgcc ctccagctca aggccggaca	1140
20	ggtgccctag agtagcctgc atccaggac aggccccagc cgggtgtga cgcattccacc	1200
	tccatctctt cctcagcacc tgagttcctg gggggaccat cagtatttctt gttccccca	1260
	aaacccaagg acactctcat gatctcccg acccctgagg tcacgtgcgt ggtggtggac	1320
25	gtgagccagg aagaccccgaa ggtccagttc aactggtacg tggatggcgt ggaggtgcatt	1380
	aatgccaaga caaagcccgcg ggaggagcag ttcaacagca cgtaccgtgt ggtcagcg	1440
	ctcaccgtcc tgcaccagga ctggctgaac ggcaaggagt acaagtgc当地 ggtctccaac	1500
30	aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggtgg gacccacggg	1560
	gtgcgaggc cacatggaca gaggtcagct cggccaccc tctgcccgg gagtgaccgc	1620
	tgtgccaacc tctgtcccta cagggcagcc cccgagagcca caggtgtaca ccctgcccc	1680
35	atcccaggag gagatgacca agaaccaggta cagcctgacc tgcctggta aaggcttcta	1740
	ccccagcgcac atcgccgtgg agtgggagag caatggcag ccggagaaca actacaagac	1800
40	cacgcctccc gtgctggact ccgcacggctc cttcttcctc tacagcaggc taaccgtgga	1860
	caagagcagg tggcaggagg ggaatgtctt ctcattgtcc gtgatgc当地 aggctctgca	1920
	caaccactac acacagaaga gcctctccct gtctctgggt aaa	1963
45	<210> 18	
	<211> 2020	
	<212> DNA	
	<213> Artificial	
50	<220>	
	<223> signal+gH9+constant domain	
	<400> 18	

**EP 2 076 539 B1**

atggaatggc cctgggtctt cctgttttc ctttctgtca caaccgggggt gcacagcgag 60  
gttcagctcg ttgaatccgg aggccgactc gtgcagccctg ggggctcctt gcggctgagc 120

5

10

15

20

25

30

35

40

45

50

55

**EP 2 076 539 B1**

	tgcgctgcc a	gtggcttac	ttttagcgat	tacaatatgg	cctgggtgcg	ccaggccccca	180
	ggcaagggtc	tggagtgggt	ggccacaatt	acctatgagg	gcagaaacac	ttattaccgg	240
5	gattcagtga	aaggcgatt	taccatcagc	aggataatg	caaagaacag	tctgtacctg	300
	cagatgaact	ctctgagagc	tgaggacacc	gctgtctact	attgtgcaag	cccacccag	360
10	tactatgagg	gctcaatcta	cagattgtgg	tttgcccatt	ggggccaggg	aacactggtg	420
	accgtctcga	gcgcttctac	aaaggggccca	tccgtcttcc	ccctggcgcc	ctgctccagg	480
	agcacctccg	agagcacagc	cgcgcctggc	tgcctggtca	aggactactt	ccccgaaccg	540
15	gtgacggtgt	cgtggaaactc	aggcgccctg	accagcggcg	tgcacacctt	cccggtgtc	600
	ctacagtctt	caggactcta	ctccctcagc	agcgtggtga	ccgtgcctc	cagcagcttg	660
	ggcacgaaga	cctacacctg	caacgttagat	cacaagccca	gcaacaccaa	ggtggacaag	720
20	agagttggtg	agaggccagc	acagggaggg	agggtgtctg	ctggaagcca	ggctcagccc	780
	tcctgcctgg	acgcaccccg	gctgtgcagc	cccagccag	ggcagcaagg	catgccccat	840
25	ctgtctcctc	acccggagggc	ctctgaccac	cccactcatg	cccagggaga	gggtcttctg	900
	gattttcca	ccaggctccg	ggcagccaca	ggctggatgc	ccctacccca	ggccctgcgc	960
	atacaggggc	aggtgctgcg	ctcagacctg	ccaagagcca	tatccggag	gaccctgccc	1020
30	ctgacctaag	cccacccaa	aggccaaact	ctccactccc	tcaagctcaga	cacttctct	1080
	cctccagat	ctgagtaact	cccaatcttc	tctctgcaga	gtccaaatat	ggtccccat	1140
	gcccaccatg	cccaggtaag	ccaaccagg	cctgcctc	cagctcaagg	cgggacaggt	1200
35	gcccttagat	agcctgcattc	cagggacagg	ccccagccgg	gtgctgacgc	atccacctcc	1260
	atctttctt	cagcacctga	gttccctgggg	ggaccatcag	tcttcctgtt	cccccaaaaa	1320
40	cccaaggaca	ctctcatgat	ctccggacc	cctgaggatca	cgtgcgtggt	ggtggacgtg	1380
	agccaggaag	accccgaggt	ccagttcaac	tggtaacgtgg	atggcgtgga	ggtgcataat	1440
	gccaagacaa	agccgcggga	ggagcagttc	aacagcacgt	accgtgtggt	cagcgtcctc	1500
45	accgtcctgc	accaggactg	gctgaacggc	aaggagtaca	agtgcaggt	ctccaacaaa	1560
	ggcctcccgat	cctccatcga	gaaaaccatc	tccaaagcca	aaggtggac	ccacgggggtg	1620
	cgagggccac	atggacagag	gtcagctcg	cccacccct	gcctggag	tgaccgctgt	1680
50	gccaacctct	gtccctacag	ggcagccccc	agagccacag	gtgtacaccc	tgccccatc	1740
	ccaggaggag	atgaccaaga	accaggtcag	cctgacctgc	ctggtaaaag	gcttctaccc	1800
55	cagcgacatc	gccgtggagt	gggagagcaa	tggcagccg	gagaacaact	acaagaccac	1860

**EP 2 076 539 B1**

gcctcccgta ctggactccg acggctcctt cttcctctac agcaggctaa ccgtggacaa 1920  
gagcaggtgg caggagggga atgtcttctc atgctccgtg atgcatgagg ctctgcacaa 1980  
5 ccactacaca cagaagagcc tctccctgtc tctgggtaaa 2020

10 <210> 19  
<211> 286  
<212> PRT  
<213> Artificial

15 <220>  
<223> IL-17A/F heterodimer

<400> 19

20 Met Gly Ile Thr Ile Pro Arg Asn Pro Gly Cys Pro Asn Ser Glu Asp  
1 5 10 15

25 Lys Asn Phe Pro Arg Thr Val Met Val Asn Leu Asn Ile His Asn Arg  
20 25 30

30 Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser Asp Tyr Tyr Asn Arg Ser  
35 40 45

35 Thr Ser Pro Trp Asn Leu His Arg Asn Glu Asp Pro Glu Arg Tyr Pro  
50 55 60

40 Ser Val Ile Trp Glu Ala Lys Cys Arg His Leu Gly Cys Ile Asn Ala  
65 70 75 80

45 Asp Gly Asn Val Asp Tyr His Met Asn Ser Val Pro Ile Gln Gln Glu  
85 90 95

50 Ile Leu Val Leu Arg Arg Glu Pro Pro His Cys Pro Asn Ser Phe Arg  
100 105 110

55 Leu Glu Lys Ile Leu Val Ser Val Gly Cys Thr Cys Val Thr Pro Ile  
115 120 125

60 Val His His Val Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly  
130 135 140

65 Gly Gly Gly Ser Gly Gly Gly Ser Arg Lys Ile Pro Lys Val Gly  
145 150 155 160

70 His Thr Phe Phe Gln Lys Pro Glu Ser Cys Pro Pro Val Pro Gly Gly  
165 170 175

**EP 2 076 539 B1**

Ser Met Lys Leu Asp Ile Gly Ile Ile Asn Glu Asn Gln Arg Val Ser  
180 185 190

5 Met Ser Arg Asn Ile Glu Ser Arg Ser Thr Ser Pro Trp Asn Tyr Thr  
195 200 205

10 Val Thr Trp Asp Pro Asn Arg Tyr Pro Ser Glu Val Val Gln Ala Gln  
210 215 220

Cys Arg Asn Leu Gly Cys Ile Asn Ala Gln Gly Lys Glu Asp Ile Ser  
225 230 235 240

15 Met Asn Ser Val Pro Ile Gln Gln Glu Thr Leu Val Val Arg Arg Lys  
245 250 255

20 His Gln Gly Cys Ser Val Ser Phe Gln Leu Glu Lys Val Leu Val Thr  
260 265 270

25 Val Gly Cys Thr Cys Val Thr Pro Val Ile His His Val Gln  
275 280 285

<210> 20

<211> 134

<212> PRT

30 <213> Artificial

<220>

<223> Cynomolgus IL-17F

35 <400> 20

Met Arg Lys Ile Pro Lys Val Gly His Thr Phe Phe Gln Lys Pro Glu  
1 5 10 15

40 Ser Cys Pro Pro Val Pro Glu Gly Ser Met Lys Leu Asp Thr Gly Ile  
20 25 30

45 Ile Asn Glu Asn Gln Arg Val Ser Met Ser Arg Asn Ile Glu Ser Arg  
35 40 45

50 Ser Thr Ser Pro Trp Asn Tyr Thr Val Thr Trp Asp Pro Asn Arg Tyr  
50 55 60

55 Pro Ser Glu Val Val Gln Ala Gln Cys Lys His Leu Gly Cys Ile Asn  
65 70 75 80

55

Ala Gln Gly Lys Glu Asp Ile Ser Met Asn Ser Val Pro Ile Gln Gln  
 85 90 95

5 Glu Thr Leu Val Leu Arg Arg Lys His Gln Gly Cys Ser Val Ser Phe  
 100 105 110

10 Gln Leu Glu Lys Val Leu Val Thr Val Gly Cys Thr Cys Val Thr Pro  
 115 120 125

15 Val Ile His His Val Gln  
 130

### Claims

1. A neutralising antibody which binds human IL-17A and human IL-17F, comprising a heavy chain and a light chain  
 20 wherein the heavy chain variable domain comprises the sequence given in SEQ ID NO:9 and the light chain variable domain comprises the sequence given in SEQ ID NO:7 or a sequence at least 95% identical thereto and wherein the antibody has an affinity for IL-17A of better than 20pM and an affinity for IL-17F of better than 2nM.
2. A neutralising antibody according to claim 1, having a heavy chain comprising the sequence given in SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7.  
 25
3. A neutralising antibody according to claim 2 which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.  
 30
4. A neutralising antibody according to any one of claims 1 to 3 wherein the antibody is a whole antibody or a functionally active fragment or derivative thereof.  
 35
5. A neutralising antibody according to claim 4 where the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or an epitope-binding fragment thereof.  
 40
6. A neutralising antibody according to claim 4 or claim 5, wherein the antibody or fragment thereof is a CDR-grafted antibody.  
 45
7. The antibody according to any one of claims 1-6, wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).  
 50
8. An isolated DNA sequence encoding the heavy and light chains of an antibody according to any one of claims 1 to 6.  
 55
9. A cloning or expression vector comprising one or more DNA sequences according to claim 8.  
 60
10. A vector according to claim 9, wherein the vector comprises the sequences given in SEQ ID NO:14 and SEQ ID NO:18.  
 65
11. A host cell for expression of an antibody according to any one of claims 1 to 6 comprising:  
 70
  - i) a DNA sequence encoding the heavy chain of said antibody, and
  - ii) a DNA sequence encoding the light chain of said antibody
 wherein the DNA sequences are provided in one or more cloning or expression vectors.  
 75
12. A host cell according to claim 11 comprising one or more cloning or expression vectors according to claim 9 or claim 10.  
 80
13. A process for the production of the antibody of any one of claims 1 to 6, comprising culturing the host cell of claim 11 and isolating the antibody.  
 85

14. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 6, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

15. A pharmaceutical composition according to claim 14, additionally comprising other active ingredients.

5 16. An antibody according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 14 or claim 15, for use in therapy.

10 17. An antibody according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 14 or claim 15, for use in the treatment or prophylaxis of a pathological disorder mediated by IL-17A and/or IL-17F or that is associated with an increased level of IL-17A and/or IL-17F wherein the pathological disorder is selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associated with infection, arthritis, rheumatoid arthritis, asthma, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme arthritis, meningoencephalitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis and Guillain-Barr syndrome, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, cancer (both solid tumours such as melanomas, hepatoblastomas, sarcomas, squamous cell carcinomas, transitional cell cancers, ovarian cancers and hematologic malignancies and in particular acute myelogenous leukaemia, chronic myelogenous leukemia, gastric cancer and colon cancer), heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, periodontitis and hypochlorhydia.

15

20

25 **Patentansprüche**

1. Neutralisierender Antikörper, der menschliches IL-17A und menschliches IL-17F bindet, umfassend eine schwere Kette und eine leichte Kette, wobei die variable Domäne der schweren Kette die Sequenz gemäß SEQ ID NO:9 und die variable Domäne der leichten Kette die Sequenz gemäß SEQ ID NO:7 oder eine damit zu wenigstens 95% identische Sequenz umfasst und wobei die Affinität des Antikörpers für IL-17A besser als 20 pM und für IL-17F besser als 2 nM ist.

2. Neutralisierender Antikörper nach Anspruch 1, mit einer die Sequenz gemäß SEQ ID NO:9 umfassenden schweren Kette und einer die Sequenz gemäß SEQ ID NO:7 umfassenden leichten Kette.

3. Neutralisierender Antikörper nach Anspruch 2, der menschliches IL-17A und menschliches IL-17F bindet, mit einer die Sequenz gemäß SEQ ID NO:15 umfassenden schweren Kette und einer die Sequenz gemäß SEQ ID NO:11 umfassenden leichten Kette.

4. Neutralisierender Antikörper nach einem der Ansprüche 1 bis 3, wobei es sich bei dem Antikörper um einen intakten Antikörper oder ein funktionell aktives Fragment oder Derivat davon handelt.

5. Neutralisierender Antikörper nach Anspruch 4, wo das Antikörperfragment ein Fab, Fab', F(ab')<sub>2</sub>, scFv oder ein epitopbindendes Fragment davon ist.

6. Neutralisierender Antikörper nach Anspruch 4 oder Anspruch 5, wobei es sich bei dem Antikörper oder Fragment davon um einen CDR-gepfropften Antikörper handelt.

7. Antikörper nach einem der Ansprüche 1-6, wobei der Antikörper bzw. das Fragment davon an ein oder mehrere Effektormolekül(e) konjugiert ist.

8. Isolierte DNA-Sequenz, codierend die schweren und leichten Ketten eines Antikörpers nach einem der Ansprüche 1 bis 6.

9. Klonierungs- oder Expressionsvektor, umfassend eine oder mehrere DNA-Sequenzen nach Anspruch 8.

50 10. Vektor nach Anspruch 9, wobei der Vektor die Sequenzen gemäß SEQ ID NO:14 und SEQ ID NO:18 umfasst.

11. Wirtszelle zur Expression eines Antikörpers nach einem der Ansprüche 1 bis 6, umfassend:

- i) eine DNA-Sequenz, die die schwere Kette des Antikörpers codiert, und
- ii) eine DNA-Sequenz, die die leichte Kette des Antikörpers codiert,

wobei die DNA-Sequenzen in einem oder mehreren Klonierungs- oder Expressionsvektoren bereitgestellt werden.

5

12. Wirtszelle nach Anspruch 11, umfassend einen oder mehrere Klonierungs- oder Expressionsvektoren nach Anspruch 9 oder Anspruch 10.

13. Verfahren zur Herstellung des Antikörpers gemäß einem der Ansprüche 1 bis 6, umfassend Kultivieren der Wirtszelle gemäß Anspruch 11 und Isolieren des Antikörpers.

14. Pharmazeutische Zusammensetzung, umfassend einen Antikörper nach einem der Ansprüche 1 bis 6 in Kombination mit einem oder mehreren aus einem pharmazeutisch unbedenklichen Hilfs-, Verdünnungs- oder Trägermittel.

## 15. Pharmazeutische Zusammensetzung nach Anspruch 14, zusätzlich umfassend weitere Wirkstoffe.

16. Antikörper nach einem der Ansprüche 1 bis 6 oder pharmazeutische Zusammensetzung nach Anspruch 14 oder Anspruch 15 zur Verwendung in der Therapie.

20 17. Antikörper nach einem der Ansprüche 1 bis 6 oder pharmazeutische Zusammensetzung nach Anspruch 14 oder Anspruch 15 zur Verwendung bei der Behandlung oder Prophylaxe einer durch IL-17A und/oder IL-17F vermittelten oder mit einem erhöhten IL-17A- und/oder IL-17F-Spiegel assoziierten pathologischen Störung, wobei die pathologische Störung aus der aus Infektionen (mit Viren, Bakterien, Pilzen bzw. Parasiten), mit Infektion assoziiertem endotoxischem Schock, Arthritis, rheumatoider Arthritis, Asthma, Beckenentzündung, Morbus Alzheimer, Morbus Crohn, Peyronie-Krankheit, Zöliakie, Gallenblasenerkrankung, Sinus pilonidalis, Peritonitis, Psoriasis, Vaskulitis, chirurgischen Adhäsionen, Schlaganfall, Typ-I-Diabetes, Lyme-Arthritis, Meningoenzephalitis, immunvermittelten entzündlichen Erkrankungen des zentralen und peripheren Nervensystems, wie etwa multipler Sklerose und Guillain-Barr-Syndrom, anderen Autoimmunerkrankungen, Pankreatitis, Trauma (Operation), Graft-versus-Host-Krankheit, Transplantatabstoßung, Krebs (sowohl soliden Tumoren wie Melanomen, Hepatoblastomen, Sarkomen, Plattenepithelkarzinomen, Urothelkarzinomen, Ovarialkarzinomen als auch bösartigen hämatologischen Erkrankungen und insbesondere akuter myeloischer Leukämie, chronischer myeloischer Leukämie, Magenkrebs und Darmkrebs), Herzkrankheit, einschließlich ischämischen Herzkrankheiten wie Myokardinfarkt ebenso wie Atherosklerose, intravaskulärer Koagulation, Knochenresorption, Osteoporose, Parodontitis und Achlorhydrie bestehenden Gruppe ausgewählt ist.

25

30

35

## Revendications

40 1. Anticorps neutralisant qui se lie à IL-17A humain et IL-17F humain, comprenant une chaîne lourde et une chaîne légère dans lequel le domaine variable de chaîne lourde comprend la séquence décrite dans SEQ ID NO: 9 et le domaine variable de chaîne légère comprend la séquence décrite dans SEQ ID NO:7 ou une séquence au moins 95 % identique à celle-ci et où l'anticorps présent une affinité pour IL-17A meilleure que 20 pM et une affinité pour IL-17F meilleure que 2 nM.

45 2. Anticorps neutralisant selon la revendication 1, ayant une chaîne lourde comprenant la séquence décrite dans SEQ ID NO: 9 et une chaîne légère comprenant la séquence décrite dans SEQ ID NO: 7.

50 3. Anticorps neutralisant selon la revendication 2 qui se lie à IL-17A humain et IL-17F humain, ayant une chaîne lourde comprenant la séquence décrite dans SEQ ID NO: 15 et une chaîne légère comprenant la séquence décrite dans SEQ ID NO: 11.

4. Anticorps neutralisant selon l'une quelconque des revendications 1 à 3 **caractérisé en ce que** l'anticorps est un anticorps entier ou un fragment ou dérivé fonctionnellement actif de celui-ci.

55 5. Anticorps neutralisant selon la revendication 4 **caractérisé en ce que** le fragment d'anticorps est un Fab, Fab', F(ab')<sub>2</sub>, scFv ou un fragment de liaison d'épitope de ceux-ci.

6. Anticorps neutralisant selon la revendication 4 ou la revendication 5, **caractérisé en ce que** l'anticorps ou fragment

de celui-ci est un anticorps greffé par CDR.

7. Anticorps selon l'une quelconque des revendications 1 à 6, **caractérisé en ce que** l'anticorps ou fragment de celui-ci est conjugué à une ou plusieurs molécule(s) effectrice(s).

5 8. Séquence d'ADN isolée codant pour les chaînes lourde et légère d'un anticorps selon l'une quelconque des revendications 1 à 6.

10 9. Vecteur de clonage ou d'expression comprenant une ou plusieurs séquences d'ADN selon la revendication 8.

10 10. Vecteur selon la revendication 9, **caractérisé en ce que** le vecteur comprend les séquences décrites dans SEQ ID NO: 14 et SEQ ID NO: 18.

15 11. Cellule hôte pour l'expression d'un anticorps selon l'une quelconque des revendications 1 à 6 comprenant :

- i) une séquence d'ADN codant pour la chaîne lourde dudit anticorps, et
- ii) une séquence d'ADN codant pour la chaîne légère dudit anticorps

20 où les séquences d'ADN sont fournies dans un ou plusieurs vecteurs de clonage ou d'expression.

20 12. Cellule hôte selon la revendication 11 comprenant un ou plusieurs vecteurs de clonage d'expression selon la revendication 9 ou la revendication 10.

25 13. Procédé de production de l'anticorps de l'une quelconque des revendications 1 à 6, comprenant la culture de la cellule hôte de la revendication 11 et l'isolement de l'anticorps.

14. Composition pharmaceutique comprenant un anticorps selon l'une quelconque des revendications 1 à 6, en combinaison avec l'un ou plusieurs d'un excipient, diluant ou véhicule pharmaceutiquement acceptable.

30 15. Composition pharmaceutique selon la revendication 14, comprenant en outre d'autres substances actives.

16. Anticorps selon l'une quelconque des revendications 1 à 6 ou composition pharmaceutique selon la revendication 14 ou la revendication 15, pour utilisation en thérapie.

35 17. Anticorps selon l'une quelconque des revendications 1 à 6 ou composition pharmaceutique selon la revendication 14 ou la revendication 15, pour utilisation dans le traitement ou la prophylaxie d'un trouble pathologique médié par IL-17A et/ou IL-17F ou qui est associé à un taux accru de IL-17A et/ou IL-17F où le trouble pathologique est choisi dans le groupe constitué d'infections (virales, bactériennes, fongiques et parasitaires), un choc endotoxique associé à une infection, l'arthrite, la polyarthrite rhumatoïde, l'asthme, une maladie inflammatoire pelvienne, la maladie d'Alzheimer, la maladie de Crohn, la maladie de La Peyronie, une maladie coeliaque, une maladie de la vésicule biliaire, une maladie pilonidale, la péritonite, le psoriasis, une vascularite, des adhérences chirurgicales, un accident vasculaire cérébral, le diabète de type I, l'arthrite de Lyme, la méningo-encéphalite, des troubles inflammatoires à médiation immunitaire du système nerveux central et périphérique tel que la sclérose en plaques et le syndrome de Guillain-Barré, d'autres troubles auto-immuns, la pancréatite, un traumatisme (chirurgie), la maladie du greffon contre l'hôte, le rejet de greffe, un cancer (à la fois des tumeurs solides telles que les mélanomes, les hépatoblastomes, les sarcomes, les carcinomes épidermoïdes, les cancers à cellules transitionnelles, les cancers de l'ovaire et les malignités hématologiques, et en particulier la leucémie myéloïde aiguë, la leucémie myéloïde chronique, le cancer de l'estomac et le cancer du côlon), une maladie cardiaque comprenant des maladies ischémiques telles qu'un infarctus du myocarde ainsi que l'athérosclérose, la coagulation intravasculaire, la résorption osseuse, l'ostéoporose, la parodontite et l'hypochlorhydrie.

Figure 1

(a) Light Chain variable region of antibody CA028\_496 (SEQ ID NO:7)

AIQLTQSPSSLSASVGDRVTITCRADESVTTLMHWYQQKPGKAPKLLIYLVSNRESGVPSRF  
SGSGSGTDFLTLSQPEDFATYYCQQTWSDPWTFGQGTKVEIKR

(b) Heavy Chain variable region of antibody CA028\_496 (SEQ ID NO:9)

EVQLVESGGGLVQPGGSLRLSCAASGFTSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRD  
SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVS  
S

(c)

CDRH1:	GFTFSDYNMA (SEQ ID NO:1)
CDRH2:	TITYEGRNTYYRDSVKG (SEQ ID NO:2)
CDRH3:	PPQYYEGSIYRLWFAH (SEQ ID NO:3)
CDRL1:	RADESVTTLMH (SEQ ID NO:4)
CDRL2:	LVSNRES (SEQ ID NO:5)
CDRL3:	QQTWSDPWT (SEQ ID NO:6)

(d) Light chain of antibody CA028\_496 (SEQ ID NO:11)

AIQLTQSPSSLSASVGDRVTITCRADESVTTLMHWYQQKPGKAPKLLIYLVSNRESGVPSRF  
SGSGSGTDFLTLSQPEDFATYYCQQTWSDPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQ  
LKSGTASVVCLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLKADY  
EKKVYACEVTHQGLSSPVTKSFNRGEC

(e) Heavy chain of antibody CA028\_496 (SEQ ID NO:15)

EVQLVESGGGLVQPGGSLRLSCAASGFTSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRD  
SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVS  
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPAVLQSSG  
LYSLSSVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPCPAPEFLGGPSVFLF  
PPPKDITLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAAKTKPREEQFNSTYRVVSV  
LTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPVYTLPPSQEEMTKNQVSLTC  
LVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH  
EALHNHYTQKSLSLSLGK

(f) DNA encoding light chain of antibody CA028\_496 including signal sequence (SEQ ID NO:14)

```

atgtcagttcccacacaggtgctgggcctgcttctgtgtggctaccgatgcttaggtgtgc
catccagactgacccagagcccttcctctcagcgcaggatgtcggagacagagtgactatta
cctgcagggctgacgaaagcgtgaccacattgatgcactggtaccaacagaaggcctggaaa
cccccaagctctgatctatctggttccaatcggagactggagttcccgaggatccatgtttcg
ccgcaggatgggtctggaaactgactttaccctgacaatctcctcactccagcccaagatcc
ccacctactattgccagcagacttggagcgacccttggacattggacaggccacaaaatgg
gagatcaagcgtacggtagcggcccatctgtcttcatcttccgcacatctgatgagcaggat
gaaatctggaaactgcctctgtgtgcctgctgaataacttctatcccagagaggccaaag
tacagtggaaagggtggataacgcgcctccaatcggtaactcccaggagagtgtcacagagcag
gacagcaaggacagcacctacagcctcagcagcaccctgacgctgagcaaagcagactacga

```

Figure 1 continued

gaaacacaaaagtctacgcctgcgaagtccccatcagggcctgagctgcggcgtcacaaga  
gcttcaacagggagagtgttag

(g) DNA encoding heavy chain of antibody CA028\_496 including signal sequence (SEQ ID NO:18)

atggaatggcctgggtttcctgttttccttctgtcacaaccgggtgcacagcgaggt  
tcagctcggtgaatccggaggcgactcgtgcagcctggggctcctgcggctgagctgcg  
ctgccagtggctcacttcagcgattacaatatggcctgggtgcgcaggccccaggcaag  
ggtctggagtggtggccacaattacctatgagggcagaaacacttattaccggattcagt  
gaaaggcgatttaccatcagcaggataatgcaaaacagtctgtacctgcagatgaact  
ctctgagagctgaggacaccgctgtctactattgtcaagccacccagttactatgagggc  
tcaatctacagattgtggttgccattggggcagggaaacactggtgcaccgtctcgagcgc  
ttctacaaaggcccattccgtttccccctggcgccctgctccaggacacccggagagca  
cagccggccctggctgcctggtaaggactacttcccgaaaccgggtgacgggtgcgtggaa  
tcaggcgccctgaccagcggcgtgcacacccctccggctgtcctacagtccctcaggactcta  
ctccctcagcagcgtggtgcaccgtgcctccagcagcttggcacgaagacactacacctgca  
acgtagatcacaagcccagcaacaccaagggtggacaagagagttggtagagggcagcacag  
ggagggagggtgtctgctggaaagccaggctcagccctctgcctggacgcacccggctgtg  
cagcccccagcccaggcagcaaggcatgcacccatctgtctccctcaccggaggcctgtgacc  
accccaactcatgcccaggaggggttttggattttccaccaggctccggcagccaca  
ggctggatgccttaccccaggccctgcgcatacaggggcaggtgctgcgcctcagacctgcc  
aagagccatatccggaggaccctgcctgacctaagccacccaaaggccaaactctcc  
actccctcagctcagacacccatctctccctccagatctgagtaactccaaatctctctg  
cagagtccaaatatggtccccatgcccaccatgcccaggtaagccaacccaggcctgc  
tccagctcaaggcggacaggtgccttagagttagcctgcatccaggacaggccccaggc  
gtgctgacgcattccacccatcttccctcagcacctgagttcctgggggaccatcagtc  
ttccctgttcccccaaaaccaaggacactctcatgatctcccgacccctgaggtcacgt  
cgtgggtggacgtgagccaggaagaccccgaggtccagttcaactggtagtggatggcg  
tggaggtgcataatgccaagacaaaggcggaggagcagttcaacacagcacgtaccgt  
gtcagcgtcctcaccgttgcaccaggactggctgaacggcaaggagtacaagtgc  
ctccaaacaaaggcctccgtcctccatcgagaaaaccatctccaaaggccaaagg  
tgggacccacgggtgcgaggggccacatggacagaggtcagctcgccaccctct  
cgctgtgcacactctgtccctacagggcagcccgagagccacagggtgacaccctgc  
catcccgaggaggatgaccaagaaccaggcgtcgcctgacccctgcctggatgg  
cccaggcgcacatcgccgtggagtggtggagagcaatggcagccggagaacaact  
gcctccctgtggactccgacggctccttccctcagcaggctaaccgtggacaaga  
gcaggtggcaggaggaaatgtcttctcatgctccgtgatgcgatgaggctctgc  
tacacacagaagacccctccctgtcttggtaaa

Figure 2a





Figure 2b



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 04106377 A [0005]
- WO 2006054059 A [0005]
- WO 2006013107 A [0005]
- WO 2006088833 A [0005]
- WO 2005010044 A [0005]
- WO 2007106769 A [0007]
- WO 2005003169 A [0013] [0089]
- WO 2005003170 A [0013] [0089]
- WO 2005003171 A [0013] [0089]
- WO 9202551 A [0016]
- WO 2004051268 A [0016]
- WO 2004106377 A [0016]
- US 5585089 A [0017]
- WO 9109967 A [0017] [0036]
- WO 9308829 A [0018]
- WO 9222853 A [0018]
- WO 05113605 A [0018]
- WO 9002809 A [0019]
- WO 9110737 A [0019]
- WO 9201047 A [0019]
- WO 9218619 A [0019]
- WO 9311236 A [0019]
- WO 9515982 A [0019]
- WO 9520401 A [0019]
- US 5698426 A [0019]
- US 5223409 A [0019]
- US 5403484 A [0019]
- US 5580717 A [0019]
- US 5427908 A [0019]
- US 5750753 A [0019]
- US 5821047 A [0019]
- US 5571698 A [0019]
- US 5516637 A [0019]
- US 5780225 A [0019]
- US 5658727 A [0019]
- US 5733743 A [0019]
- US 5969108 A [0019]
- US 4946778 A [0019]
- WO 9306231 A [0070]
- WO 9222583 A [0070]
- WO 8900195 A [0070]
- WO 8901476 A [0070]
- WO 03031581 A [0070]
- WO 8601533 A [0070]
- EP 0392745 A [0070]
- US 4741900 A [0076]
- WO 05117984 A [0077]
- US 5219996 A [0085]
- US 5667425 A [0085]
- WO 9825971 A [0085] [0088]
- EP 0948544 A [0087]
- WO 2004072116 A [0088]
- WO 9820734 A [0113]
- WO 04051268 A [0137]
- WO 06054059 A [0142]

## Non-patent literature cited in the description

- FOSSIEZ *et al.* *Int.Rev.Immunol.*, 1998, vol. 16, 541-551 [0002]
- YAO *et al.* *Cytokine*, 1997, vol. 9, 794-800 [0002]
- TOY *et al.* *J. Immunol.*, 2006, vol. 177 (11), 36-39 [0002]
- WEAVER *et al.* *Immunity*, 2006, vol. 24, 677-688 [0002]
- LANGOWSKI *et al.* *IMMUNITY*, 2006, vol. 442, 461-465 [0002]
- IWAKURA ; ISHIGAME. *J.Clin.Invest.*, 2006, vol. 116 (5), 1218-1222 [0002]
- DUMONT. *Expert Opin. Ther. Patents*, 2003, vol. 13, 287-303 [0003]
- KOLLS ; LINDEN. *Immunity*, 2004, vol. 21, 467-476 [0003]
- HYMOWITZ *et al.* *EMBO J.*, 2001, vol. 20 (19), 5332-5341 [0003]
- KUESTNER *et al.* *Journal of Immunology*, 2007, vol. 179, 5462-5473 [0003]
- WRIGHT *et al.* *J. Biol. Chem.*, 2007, vol. 282 (18), 13447-13455 [0004]
- LUBBERTS *et al.* *J.Immunol.*, 2001, vol. 167, 1004-1013 [0005]
- CHABAUD *et al.* *Arthritis Res.*, 2001, vol. 3, 168-177 [0005]
- CHUNG *et al.* *J. Exp. Med.*, 2002, vol. 195, 1471-1478 [0005]
- KAWAGUCHI *et al.* *J.Allergy Clin. Immunol.*, 2006, vol. 117 (4), 795-801 [0006]
- LUBBERTS. *Current Opinion in Investigational Drugs*, 2003, vol. 4 (5), 572-577 [0006]
- Handbook of Experimental Immunology. Blackwell Scientific Publishers, 1986, vol. 4 [0012]

- **VERMA et al.** *Journal of Immunological Methods*, 1998, vol. 216, 165-181 [0013]
- **LAWSON**. Therapeutic antibodies. *Drug Design Reviews - Online*, 2005, vol. 2 (3), 209-217 [0013]
- **KOHLER ; MILSTEIN**. *Nature*, 1975, vol. 256, 495-497 [0015]
- **KOZBOR et al.** *Immunology Today*, 1983, vol. 4, 72 [0015]
- **COLE et al.** Monoclonal Antibodies and Cancer Therapy. Alan R Liss, Inc, 1985, 77-96 [0015]
- **BABCOOK, J. et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93 (15), 7843-78481 [0016]
- **MILSTEIN et al.** *Nature*, 1983, vol. 305, 537-539 [0018]
- **TRAUNECKER et al.** *EMBO J.*, 1991, vol. 10, 3655-3659 [0018]
- **BRINKMAN et al.** *J. Immunol.*, 1995, vol. 182, 41-50 [0019]
- **AMES et al.** *J. Immunol. Methods*, 1995, vol. 184, 177-186 [0019]
- **KETTLEBOROUGH et al.** *Eur. J. Immunol.*, 1994, vol. 24, 952-958 [0019]
- **PERSIC et al.** *Gene*, 1997, vol. 187, 9-18 [0019]
- **BURTON et al.** *Advances in Immunology*, 1994, vol. 57, 191-280 [0019]
- **CHOTHIA, C. ; LESK, A.M.** *J. Mol. Biol.*, 1987, vol. 196, 901-917 [0022]
- Computational Molecular Biology. Oxford University Press, 1988 [0030]
- Biocomputing. Informatics and Genome Projects. Academic Press, 1993 [0030]
- Computer Analysis of Sequence Data. Humana Press, 1994 [0030]
- **VON HEINJE, G.** Sequence Analysis in Molecular Biology. Academic Press, 1987 [0030]
- Sequence Analysis Primer. M Stockton Press, 1991 [0030]
- **VAUGHAN et al.** *Nature Biotechnology*, 1998, vol. 16, 535-539 [0033]
- **KASHMIRI et al.** *Methods*, 2005, vol. 36, 25-34 [0033]
- **RAVETCH, JV. et al.** *Cell*, 1981, vol. 27, 583-591 [0034]
- **HIETER, PA. et al.** *J. Biol. Chem.*, 1982, vol. 257, 1516-1522 [0035]
- **REICHMANN et al.** *Nature*, 1998, vol. 332, 323-324 [0036]
- **ANGAL et al.** *Molecular Immunology*, 1993, vol. 30 (1), 105-108 [0046]
- **YANG et al.** *J. Mol. Biol.*, 1995, vol. 254, 392-403 [0068]
- **MARKS et al.** *Bio/Technology*, 1992, vol. 10, 779-783 [0068]
- **LOW et al.** *J. Mol. Biol.*, 1996, vol. 250, 359-368 [0068]
- **PATTEN et al.** *Curr. Opin. Biotechnol.*, 1997, vol. 8, 724-733 [0068]
- **THOMPSON et al.** *J. Mol. Biol.*, 1996, vol. 256, 77-88 [0068]
- **CRAMERI et al.** *Nature*, 1998, vol. 391, 288-291 [0068]
- **HELLSTROM et al.** Controlled Drug Delivery. 1987, 623-53 [0070]
- **THORPE et al.** *Immunol. Rev.*, 1982, vol. 62, 119-58 [0070]
- **DUBOWCHIK et al.** *Pharmacology and Therapeutics*, 1999, vol. 83, 67-123 [0070]
- **CHAPMAN**. *Advanced Drug Delivery Reviews*, 2002, vol. 54, 531-545 [0083]
- Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications. Plenum Press, 1992 [0087]
- Poly(ethyleneglycol) Chemistry and Biological Applications. American Chemical Society, 1997 [0087]
- **M. ASLAM ; A. DENT**. Bioconjugation Protein Coupling Techniques for the Biomedical Sciences. Grove Publishers, 1998 [0087]
- **CHAPMAN, A.** *Advanced Drug Delivery Reviews*, 2002, vol. 54, 531-545 [0087]
- **WHITTLE et al.** *Protein Eng.*, 1987, vol. 1 (6), 499-505 [0094]
- Current Protocols in Molecular Biology. Wiley Interscience, 1999 [0096]
- Maniatis Manual produced. Cold Spring Harbor Publishing [0096]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1991 [0116]

## Szabadalmi igénypontok

1. Semlegesítő ellenanyag, amely humán IL-17A-t és humán IL-17F-t köt, amely nehézláncot és könnyüláncot tartalmaz, ahol a nehézlánc variabilis domén a SEQ ID NO:9 szerinti szekvenciát tartalmaz és a könnyülánc variabilis domén a SEQ ID NO:7 szerinti szekvenciát tartalmaz vagy azokkal legalább 95%-ban azonos szekvenciát, és ahol az ellenanyag affinitása az IL-17A-ra jobb mint 20pM és az affinitása az IL-17F-ra jobb mint 2nM.

2. Az 1. igénypont szerinti semlegesítő ellenanyag, amely SEQ ID NO:9 szerinti szekvenciát tartalmazó nehézláncot és SEQ ID NO:7 szerinti szekvenciát tartalmazó könnyüláncot rendelkezik.

3. A 2. igénypont szerinti semlegesítő ellenanyag, amely humán IL-17A-t és humán IL-17F-t köt, amely SEQ ID NO:15 szerinti szekvenciát tartalmazó nehézláncot és SEQ ID NO:11 szerinti szekvenciát tartalmazó könnyüláncot rendelkezik.

4. Az 1-3. igénypontok bármelyike szerinti semlegesítő ellenanyag, ahol az ellenanyag teljes ellenanyag vagy annak funkcionálisan aktív fragmense vagy származéka.

5. A 4. igénypont szerinti semlegesítő ellenanyag, ahol az ellenanyag-fragmens Fab, Fab', F(ab')<sub>2</sub>, scFv vagy annak építőpkötő fragmense.

6. A 4. vagy 5. igénypont szerinti semlegesítő ellenanyag, ahol az ellenanyag vagy fragmense CDR-graftot ellenanyag.

7. Az 1-6. igénypontok bármelyike szerinti ellenanyag, ahol az ellenanyag vagy fragmense egy vagy több effektor-molekulához van konjugálva.

8. Izolált DNS-szekvencia, amely az 1-6. igénypontok bármelyike szerinti ellenanyag nehéz- és könnyüláncait kódolja.

9. Klónozó vagy expressziós vektor, amely egy vagy több 8. igénypont szerinti DNS-szekvenciát tartalmaz.

10. A 9. igénypont szerinti vektor, ahol a vektor a SEQ ID NO:14 és SEQ ID NO:18 szerinti szekvenciát tartalmaz.

11. Gazdasejt az 1-6. igénypontok bármelyike szerinti ellenanyag expresszálására, amely tartalmaz:

- i) az ellenanyag nehézláncát kódoló DNS-szekvenciát, és
- ii) az ellenanyag könnyüláncát kódoló DNS-szekvenciát,

ahol a DNS-szekvenciák egy vagy több klónozó vagy expressziós vektoron vannak biztosítva.

12. A 11. igénypont szerinti gazdasejt, amely egy vagy több 9. vagy 10. igénypont szerinti klónozó vagy expressziós vektort tartalmaz.

13. Eljárás az 1-6. igénypontok bármelyike szerinti ellenanyag előállítására, amely magában foglalja a 11. igénypont szerinti gazdasejt tenyésztését és az ellenanyag izolálását.

14. Gyógyászati készítmény, amely 1-6. igénypontok bármelyike szerinti ellenanyagot tartalmaz, kombinációban egy vagy több gyógyászatilag elfogadható excipientssel, hígítószerekkel vagy hordozóval.

15. A 14. igénypont szerinti gyógyászati készítmény, amely továbbá más hatóanyagokat is tartalmaz.

16. Az 1-6. igénypontok bármelyike szerinti ellenanyag vagy a 14. vagy 15. igénypont szerinti gyógyászati készítmény, terápiában történő alkalmazásra.

17. Az 1-6. igénypontok bármelyike szerinti ellenanyag vagy a 14. vagy 15. igénypont szerinti gyógyászati készítmény, IL-17A és/vagy IL-17F által közvetített vagy az IL-17A és/vagy IL-17F megnövekedett szintjével kapcsolatos patológiás rendellenesség kezelésében vagy profilaxisában történő alkalmazásra, ahol a patológiás rendellenesség a következők által alkotott csoportból van kiválasztva: fertőzések (vírusos, bakteriális, gombás és parazitás), fertőzéssel kapcsolatos endotoxikus sakk, izületi gyulladás, reumás izületi gyulladás, asztma, medencei gyulladásos betegség, Alzheimer-kór, Crohn-betegség, Peyronie-betegség, coeliakia, epehólyag-betegség, Pilonidal betegség, hashártyagyulladás, pszoriázis, vaszkultíusz, sebészeti összenövések, stroke, I-es típusú cukorbetegség, Lyme izületi gyulladás, meningoencefalítisz, a központi és perifériás idegrendszer immunközvetített gyulladásos rendellenességei, mint például a multiplex szklerózis és Guillain-Barr-szindróma, egyéb autoimmun rendellenességek, hasnyálmirigy-gyulladás, trauma (műtét), graft-versus-host betegség, transzplantátum-kilöködés, rák (mind a szilárd tumorok, például melanóma, hepatoblasztómák, szarkómák, pikkelysejtes karcinómák, átmeneti sejtes rákok, petefészek-rák, mind a rosszindulatú hematológiás tumorok és különösen az akut mielogén leukémia, krónikus mielogén leukémia, gyomorrák és vastagbélrák), szívbetegség, beleértve ischaemias betegségek, mint például miokardiális infarktus, valamint érrendszeresedés, intravaszkuláris koaguláció, csontfelszívódás, oszteoporózis, periodontitisz és hypochlorhydia.